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General Introduction
GENERAL OVERVIEW OF DUPUYTREN’S DISEASE
Dupuytren’s disease is a chronic progressive fibroproliferative disorder 
of the palmar fascia characterized by flexion contractures of the fingers.1 It 
is named after Baron Guillaume Dupuytren, who described the disorder in 
1831. However, it was earlier described by Felix Platter (1680), Henry Cline 
(1808) and Sir Astley Cooper (1818).2
Classically, the first sign of Dupuytren’s disease is the formation of palmar 
nodules. These nodules are the result of myofibroblast proliferation and ex-
tracellular matrix synthesis.3 When the disease progresses, these nodules 
develop into fibrotic cords, which lead to digital contractures.4 Finally, these 
contractures can lead to the loss of hand function and diminished quali-
ty-of-life in patients with Dupuytren’s disease.5 Dupuytren’s disease is more 
prevalent in Caucasian, older males. Prevalence rates vary from 0.2% to 56% 
depending on the population studied.6 A recent study in the Netherlands 
reported an overall incidence of 22.1%.7
Various risk factors have been linked to Dupuytren’s disease of which fa-
milial predisposition is one of the strongest.8 Genetic abnormalities and 
pathways for Dupuytren’s disease have been described.9,10 Other risk factors 
include smoking, alcohol consumption, excessive vibrations, manual labor, 
hand trauma and diabetes.7,11-13 The precise role of these risk factors in the 
pathogenesis remains unclear. Overall, Dupuytren’s disease is likely to be a 
multifactorial and polygenic condition.14
CLINICAL PRESENTATION AND TREATMENT OPTIONS
The clinical presentation of Dupuytren’s disease varies greatly depending 
on the location and severity of the contractures. Contractures are most com-
monly seen in the metacarpophalangeal (MCP) and proximal interphalangeal 
(PIP) joints of the fourth and fifth digit of the hand. However, other fingers can 
be affected as well as interdigital web spaces.15 The severity of the disease is 
determined by the underlying biology of the disease, known as the Dupuy-
tren’s diathesis. Factors that influence the Dupuytren’s diathesis are bilateral 
hand involvement, ectopic disease, a positive family history for Dupuytren’s 
disease, male gender and an early onset of the disease. A more severe dia-
thesis will result in a higher prevalence of recurrence.16 
A variety of treatment options exist for Dupuytren’s disease depending on 
the location of the contracture(s) and the severity of the disease. Surgery has 
been the mainstay of treatment, as it provides long-lasting correction.17 How-
12
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ever, factors such as complication rates and return-to-work, also play a role in 
treatment choice.18 Most common treatment options, increasing in invasive-
ness, are: collagenase injections, percutaneous needle fasciotomy, limited 
fasciectomy and dermofasciectomy.
Collagenase injections are gaining in popularity as they are minimal-inva-
sive and do not require formal surgery.19 Collagenase can be injected at one 
to several points along the fibrotic cord. The collagenase enzymes cleave the 
collagen, which results in weakening of the cord. One to four days later the 
cord can be broken by straightening the finger.20 Results in terms of straight-
ness of the finger after treatment are good and major complications are low. 
However, minor complication rates, such as hematomas and skin tears, are 
high.21,22 Collagenase injections are relatively new, but the first studies show 
a high recurrence rate at follow-up (3-year: 35%, 5-year: 47%).23 The use of 
collagenase in the Netherlands is limited as healthcare insurances do not re-
imburse the use of collagenase injections.
Percutaneous needle fasciotomy (PNF) is a minimal-invasive technique in 
which the cord is transected percutaneously.24,25 It is commonly used for con-
tractures in the MCP joint, where a clear cord is palpable. It has a low compli-
cation rate and quick recovery.26,27 The disadvantage is the high percentage 
of recurrence (3-year: 58%, 5-year: 85%).17,26
Limited fasciectomy (LF) is the most commonly used treatment for Dupu-
ytren’s disease. An incision is made over the affected fascia after which the 
pathological fascia is removed. Care must be taken not to damage the neuro-
vascular bundles or the flexor tendons. Recurrence rates are lower compared 
to PNF (5-year: 20.9%).17 However, the complication rates are higher then for 
PNF and recovery after surgery takes considerably longer.28
Dermofasciectomy involves the removal of the skin together with the affect-
ed fascia and a full thickness graft is used to close the skin. It is reserved for 
patients with severe diathesis and recurrent cases. Recurrence under a skin 
graft is rare.29,30
OUTCOME MEASUREMENTS
In Dupuytren’s disease it is generally assumed that improvement of the 
hand function is an important goal for patients seeking treatment. Therefore, 
hand function is, alongside complication- and recurrence rates, an important 
outcome measurement in determining the success of treatment. This hand 
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function can be measured in various ways. Performance-based measures 
such as the improvement in range of motion are widely used and provide an 
objective measurement of hand function. Additionally, so-called patient-re-
ported outcome measures (PROMs) are used. These questionnaires reflect 
the patient’ perspective on the impact of the disease and its treatment on 
hand function. 
The treatment of Dupuytren’s disease is aimed at improving the range of 
motion of a finger or fingers (that is, reduce the digital contracture(s)), which 
should lead to improvement in hand function. However, several studies have 
shown that an increase in range of motion is poorly correlated with an im-
provement in patient-reported hand function.31,32 Comparative studies be-
tween various treatments have shown that, despite similar contracture re-
duction, differences exist in patient-assessed hand function and satisfaction 
with hand function.33,34 These results demonstrate that improvement of the 
patient-reported hand function is not simply achieved by correcting the ex-
tension deficit of patients.
14
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AIMS OF THIS THESIS 
This discrepancy between performance-based outcome measures and pa-
tient-reported outcome measures in Dupuytren’s disease is remarkable and 
not fully understood. In order to improve outcome of Dupuytren’s disease a 
good understanding of its underlying pathophysiology is needed. However, 
especially in patient-centered care, measuring and understanding what is im-
portant for a patient is fundamental to understanding the burden of disease 
and the success of treatment.35 
The overall aim of this thesis was to explore the various outcome measures 
in Dupuytren’s disease and how these outcome measures are influenced by 
patient- and disease characteristics and treatment. To do so, this thesis has 
been divided in four parts. In the first part we introduce the Hand and Wrist 
Cohort, which forms the basis of this study. In the second part we explore 
psychologically orientated factors in patients with chronic hand- and wrist 
disorders and how these factors influence the (perceived) hand function. In 
the third part, we study the advantages and pitfalls of various outcome mea-
sures for Dupuytren’s disease and determine which measurements are most 
beneficial for recording outcome in Dupuytren’s disease. In the final part, we 
examine to which extent pre-operative patient- and disease characteristics 
can reliably predict outcome in Dupuytren’s disease.
OUTLINE OF THIS THESIS
To study the questions asked in this thesis an open, prospectively main-
tained cohort of patients with hand and wrist disorders, including Dupuy-
tren’s disease, is introduced in Chapter 2.
As there are many psychologically orientated factors which potentially have 
a role in perceived hand function, this thesis focuses on two of those factors. 
First, we studied the perception of illness in patients with chronic hand and 
wrist disorders, including Dupuytren’s disease (Chapter 3). Second, we ex-
amine the relationship between experience with healthcare delivery and out-
come measures in Dupuytren’s disease (Chapter 4).
The current standard to measure patient-reported hand function is with 
standardized, pre-defined questionnaires. These questionnaires are widely 
used and well validated for various hand- and wrist disorders. Nonetheless, 
they might be less applicable for patients with Dupuytren’s disease, as the 
pre-defined nature might not capture all functional problems.36 In Chapter 5 
15
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we evaluate the use of the Patient Specific Functional Scale (PSFS), a so-called 
individualized PROM, in patients with Dupuytren’s disease. 
It is generally accepted that hand function is the main outcome parameter 
in Dupuytren’s disease, either as a performance-based or as a patient-report-
ed outcome measure. However, there is evidence from other hand disorders 
that other outcome parameters, such as hand appearance, are of importance 
to patients.37,38 Therefore, in Chapter 6, we evaluate what other outcome pa-
rameters might be of importance to patients with Dupuytren’s disease. 
Although a disease which mainly affects the older population, half of the pa-
tients with Dupuytren’s disease is working at the moment they seek treatment. 
For these patients, return to work might be an important (additional) outcome 
measurement. However, very little is known about return to work after treat-
ment for Dupuytren’s disease. In Chapter 7 we aim to fill this void.
The progressive character of Dupuytren’s disease results in recurrence of 
digital contractures after initial treatment in numerous patients. In Chapter 8 
the hand function of patients after repeated treatment is compared to that of 
the same patients after initial treatment.
As shared decision making becomes more and more important, so does the 
need for reliable information about post-operative results. In Chapter 9 we 
explore to which extent pre-operative patient- and disease characteristics can 
reliably predict a complete finger extension after surgery.
Finally, in Chapter 10, we discuss the main findings from this thesis and im-
plications for future research.
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ABSTRACT
Routine measurement of outcome of clinical care is increasingly consid-
ered important, but implementation in practice is challenging. This paper 
describes how 1) we created and implemented a routine outcome measure-
ment cohort of patients with hand and wrist conditions, and 2) these data are 
used to improve the quality of care and facilitate scientific research. Starting 
in 2011, routine outcome measurement was implemented at all practice sites 
(currently 22) of a specialized treatment center for hand and wrist conditions 
across the Netherlands. We developed five ‘measurement tracks’, including 
measurements administered at predetermined time points covering all hand 
and wrist disorders and treatments. An online system automatically distrib-
utes measurements amongst patients, which can be accessed by healthcare 
professionals. Using this system, the total number of yearly assigned tracks 
increased up to over 16.500 in 2018, adding up to 85.000 tracks in 52.000 
patients in total. All surgeons, therapists, and other staff have direct access to 
individual patient data and patients have access to their treatment informa-
tion using a secure patient portal. The data serves as a basis for studies on, 
amongst others, comparative effectiveness, prediction modeling, and clini-
metric analyses. In conclusion, we present the design and successful imple-
mentation of a routine outcome measurement system that was made feasible 
using a highly automated data collection infrastructure, tightly linked to the 
patient journey and the workflow of healthcare professionals. The system not 
only serves as a tool to improve care but also as a basis for scientific research 
studies. 
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INTRODUCTION
Routine measurement of the outcome of clinical care is increasingly con-
sidered important in healthcare. It is a key aspect of value-based healthcare, 
patient-centered care, and other quality of care initiatives.1 For example, 
the Dutch government strives to have objective outcome data on 50% of all 
healthcare in 2022,2 while in Sweden outcome measurements have been part 
of a national registry for years.3 
 The goals of routine outcome measurement are multitude, including im-
proving communication and treatment guidance at patient level, as well as 
benchmarking of outcome at the level of individual clinicians or treatment 
centers. This benchmark information may help to establish priorities in re-
source allocation, and provide clinicians and managers with valuable feed-
back on performance. Furthermore, routine outcome measurement systems 
generate large datasets that can be used in scientific research. This so-called 
‘big data’ can help provide knowledge on, for example, comparative effec-
tiveness, predictive factors of outcome, and psychometric properties of mea-
surement instruments.
While routine outcome measurement has been advocated for years, im-
plementation in clinical practice is limited due to several challenges. These 
include lack of 1) consensus on which outcome measurements to be collect-
ed; 2) appropriate IT infrastructure for data collection; 3) time and financial 
resources for data collection; 4) compliance of both patients and healthcare 
providers in data collection; 5) analysis and visualization tools and; 6) knowl-
edge to improve clinical care by using the data. 
In 2009, Xpert Clinic, Handtherapie Nederland and Erasmus MC - University 
Medical Center Rotterdam started an initiative to collect routine outcome data 
in all patients with hand and wrist disorders undergoing surgical or non-sur-
gical treatment in their centers. This paper provides an overview of this rou-
tine outcome measurement cohort by describing its design, development, 
and implementation. Furthermore, we describe how the accumulated data 
are used to improve the quality of healthcare and facilitate ongoing scientific 
research. By sharing our lessons learned, we hope to help others overcome 
the hurdles to implement routine outcome measurement.
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METHODS
Treatment locations and patient population
Routine outcome measurement was implemented in 2011 at all practice 
sites (currently 22) of Xpert Clinic and Handtherapie Nederland across the 
Netherlands. Presently, 23 European Board certified (FESSH) hand surgeons, 
multiple hand surgery fellows, and >150 hand therapists are employed with-
in these organizations. The organizations provide non-surgical and surgical 
treatment for acute and non-acute hand and wrist disorders, excluding emer-
gency care. Patients are referred by either their general practitioner or anoth-
er medical specialist. Surgical treatment is only performed in patients with an 
American Society of Anesthesiologists score (ASA) of 1-2. Table 1 shows an 
overview of the most common disorders and treatments. 
Prior to any measurement or treatment, all patients are digitally asked for 
permission to use their data anonymously for scientific research. If a pa-
tient does not provide informed consent, the data will only be used for di-
rect healthcare purposes but not for scientific analysis. Patients can always 
withdraw their consent. Access to all questionnaires, including the one on 
informed consent, is restricted through the use of a unique secret identifier 
provided to the individual patient by email. Approval from local medical ethi-
cal review board is obtained for each scientific study that uses the data. 
Measurements
In 2010, a working group consisting of hand surgeons, hand therapists and 
researchers from Xpert Clinic, Handtherapie Nederland and Erasmus MC de-
veloped a measurement set based on existing guidelines.7 Instruments were 
considered if they were of direct use for clinical care, quality assessment, or 
treatment outcome evaluation and had proper psychometric properties.7 
Table 1 (opposite page). Overview of how the primary interventions performed 
on patients in this study and how they are organized into the measurement tracks. 
Grouping is based on similar outcome domains and follow-up periods needed to 
capture the health status of the patient after and intervention. If a patient receives 
multiple treatments, only one track is assigned based on a priority rule. The tracks 
are ordered from left to right based on this priority. Hence, for example, when Du-
puytren surgery (Dupuytren track) and a trigger finger release (Finger Regular track) 
are performed at the same time, only the Dupuytren track is assigned because it has 
a higher priority. Moreover, when a treatment is started with a higher track priority 
(e.g., trapeziectomy with the Thumb Extended track) then the earlier assigned track 
(e.g., non-surgical treatment for thumb osteoarthitis with Thumb Regular track), the 
earlier track is stopped and the new track is assigned.
28
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Table 2. Overview of the predefined tracks, their measurements and time points. 
This table shows the measurements performed in all tracks and the additional mea-
surements performed in each specific track. For each type of treatment, it was de-
cided whether patients would be assigned a regular track with a short follow-up of 
maximally three months or an extended track with a 12-month follow-up and more 
extensive measurements. Measurements performed only in the extended tracks for 
a specific time points are denoted by an asterix (*).





































































































MHQ, Michigan Hand Outcome Questionnaire; VAS, Visual Analog Scale; VAS Function, Visual Analogue 
Scale for hand function; PREM, Patient Reported Experience Measure; PRWHE, Patient Rated Wrist-Hand 
Evaluation; BCTQ, Boston Carpal Tunnel Questionnaire; ROM, range of motion; Satisfaction, satisfaction with 
the outcome of treatment; PSFS, patient specific function scale.
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Measurements only relevant for scientific research or analyses of underlying 
pathology (e.g., radiographic imaging or electromyography) were excluded 
from routine registration. All measurements were kept to a minimum to re-
duce the burden and optimize compliance. 
The Clinician Reported Outcome Measurements (CROMs) include grip & 
pinch strength and range of motion, while Patient Reported Outcome Mea-
surements (PROMs) include pain, hand function, aesthetics, return to work/
daily activities, and satisfaction with the outcome. Furthermore, a Dutch Pa-
tient Reported Experience Measure (PREM) is used.8 
Next, we created ‘measurement tracks’ comprising a specific set of measure-
ments administered at predetermined time points for each treatment or con-
dition. We aimed to create as few measurement tracks as possible, based on 
similarity in the relevance of outcome domains and time points needed to cap-
ture the patients’ health status. Eventually, five main measurement tracks were 
developed: 1) thumb disorders; 2) wrist disorders; 3) finger disorders; 4) Dupu-
ytren’s disease; and 5) compression neuropathy. The thumb, wrist, and finger 
tracks were further divided into a ‘regular’ track (including shorter follow-up and 
fewer measurements, e.g., for trigger finger) and an ‘extended’ track (includ-
ing longer follow-up and more measurements, e.g., for thumb base surgery). 
For all measurement tracks, selected time points were base-
line and combinations of six weeks, three, six, and twelve months 
post-treatment (see Table 2). Table 2 shows the content of each mea-
surement track, which is reviewed and updated every two years. 
If a patient receives multiple concurrent treatments, only one track is assigned 
at treatment onset by the hand therapist in collaboration with the hand sur-
geon. To select this single track, we developed a priority rule based on the 
treatment that we expected, on average, to have the most impact (see Table 
1). Although only a single track is assigned in these cases, all concurrent treat-
ments are registered. The same priority rule is applied when a new treatment 
starts during an already active measurement track, e.g. three months postop-
eratively to determine if a new track needs to be assigned. 
Measurement logistics and data collection
For efficient implementation of routine outcome measurement, measure-
ment time points were aligned with the sequence of care events of typical pa-
tients (see Figure 1). For example, when a first consultation is registered in the 
electronic patient record, this initiates the distribution of baseline question-
naires assessing risk factors (e.g., smoking, comorbidity, and medical history) 
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Figure 1. Flowchart of measurement timing relative to common care paths of pa-
tients. Since the measurement system is coupled to electronic patient records with 
care information, measurements, and questionnaires emailed to patients, it can be 
fully automated as soon as non-surgical or surgical treatment is entered into the 
system.
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and patient expectations of the consultation and treatment. Then, during the 
first consultation, a hand surgeon registers the diagnosis and decides togeth-
er with the patient to start either non-surgical or surgical treatment. Based on 
this information, a hand therapist assigns a specific measurement track. At 
the same visit, the hand therapist records patients demographics (e.g., hand 
dominance) and CROMs and informs the patient on the treatment and future 
measurements. Subsequently, PROMs are e-mailed to the patient. The start 
of non-surgical treatment or the date of surgery determines the timing of fu-
ture questionnaires or assessments. To guarantee the validity and reliability 
of our data, all therapists received specific training on performing the mea-
surements. 
All data are collected digitally in an online system named Pulse, which was 
developed using GemsTracker electronic data capture tools.9 GemsTracker 
is a secure, open-source, web-based application for distribution of question-
naires and forms for clinical research and quality registration. GemsTracker 
uses the open-source software LimeSurvey10 for building and storing ques-
tionnaires. To ensure data safety, measurements are administered using meth-
ods similar to those in electronic patient records, including annual audits and 
tests, two-way authentication login, and logging and monitoring of all activity. 
Since Pulse is linked to our electronic patient records, it automatically sends 
invitational emails to patients for completing questionnaires as soon as a di-
agnosis and treatment onset are assigned to a patient in the electronic pa-
tient record. Also, healthcare providers can access Pulse and see which mea-
surements they need to complete for a specific patient. 
Pulse directly calculates scores of PROMs and displays an overview of an-
swered, open, and missed measures. When the same measure is adminis-
tered multiple times within a track, score development over time is displayed. 
In the case PROM data are missing, the surgeon or therapist can request the 
patient to complete the missing questionnaires, but treatment can also con-
tinue without this information.
RESULTS
Collected data
Figure 2 shows the number of tracks assigned to patients over the years. 
The total number of yearly assigned tracks increased up to over 16.300 in 
2018, adding up to a total of 85.000 tracks in 52.000 patients. The increase 
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Table 3. The total number of patient questionnaires (across all tracks) and the medi-
an time to complete the questionnaires is shown for the period 2011-2018.
Questionnaire Number of completed 
questionnaires
Median time to complete
MHQ 49925 4:15 min
PRWHE 28784 3:43 min
BCTQ 17680 1:54 min
Return to Work 40998 0:39 min
Satisfaction with Result 81534 0:14 min
VAS pain and function 135074 0:33 min
PREM 25407 4:17 min
MHQ,: Michigan Hand Outcome Questionnaire; PRWHE, Patient Rated Wrist-Hand Evaluation; BCTQ, Boston 
Carpal Tunnel Questionnaire; VAS, Visual Analog Scale; PREM, Patient Reported Experience Measure.
Figure 2. The number of yearly activated measurement tracks. Dashed lines indi-
cate the regular tracks, solid lines the extended tracks. Note that more than one 
measurement track can be assigned to a patient, for example when a new treatment 
track (e.g., surgery) is initiated after an initial treatment track failed to obtain suffi-
cient relief of symptoms (e.g., an injection or hand therapy). The decrease in track 
assignment in 2015 and 2016 was due to organizational problems leading to a sig-
nificant number of patients where a measurement track was not assigned at the start 
of treatment. However, as can be seen below, this improved by 2017.
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in the track numbers reflects the growth in treatment volume and the open-
ing of new centers. The regular tracks, which include non-surgical treatments 
(e.g., orthotics, exercise therapy, injections) and minor surgical interventions 
(e.g., trigger finger release), were more often assigned than extended tracks, 
which include more invasive surgery. Table 3 shows that the Michigan Hand 
outcomes Questionnaire (MHQ), Patient-Rated Wrist/Hand Evaluation (PR-
WHE) and our PREM are the most time-consuming measures, with a median 
of 3-4 minutes to complete. These completion times are lower than initially 
reported; for example, the MHQ is reported to take ±15 minutes to complete 
according to its developers.11
Patient compliance for completing questionnaires was highest at baseline. 
For example, for pain, hand function, and satisfaction questionnaires, com-
pliance was 73% at baseline and decreased to 62% at 12 months (see Figure 
3a). Compliance in extended tracks was 8% higher at baseline and 14% high-
er at three months compared to regular tracks. Compliance also decreased 
at follow-up for CROMs (Figure 3b); at baseline, 90% of measurement forms 
were completed, while at 3 and 12 months these numbers decreased to 50% 
and 38% respectively. 
Using outcome data in clinical practice
From the start in 2011, all surgeons, therapists, and staff had direct access to 
all scores of individual patients and their development over time. Hence, for 
example, hand therapists use the measurements to evaluate treatment prog-
ress and set new treatment goals. Also, we introduced an integrated secure 
patient portal (Figure 4) to allow patients to access their treatment informa-
tion. Within this portal, patients can complete their questionnaires and see 
their progress over time. Based on the assigned treatment, patient-specific 
treatment information is provided, e.g., disease-specific instructional videos 
on postoperative exercises. In 2018, approximately 3100 patients logged into 
their patient portal each month. 
From 2017 onwards, we show individual patient outcomes relative to the 
average outcome from previous patients. For example, patients can see their 
pain score over time relative to mean scores of previous patients undergoing 
the same treatment (Figure 5). Moreover, we introduced a physician dash-
board, where physician-specific outcomes for >100 treatments are compared 
to the average of all other physicians. 
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Figure 3a. Compliance of patients completing the patient-reported outcome mea-
surements, illustrated using the compliance on the Visual Analogue Scale for pain, 
hand function, and satisfaction. There are differences in compliance between mea-
surement tracks, but the most important factor is the duration of the follow-up.
Figuere 3b. Compliance of hand therapists filling in the clinician-reported outcome 
measurements, such as goniometry and grip strength.
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Scientific research with the collected data
While our data collection system was primarily designed to improve and 
monitor the quality of healthcare of our patients, the system also constitutes 
a cohort of high-quality data suitable for scientific research: the Hand-Wrist 
Study Group Cohort. 
Comparative effectiveness and prediction modeling
Our first published studies12-16 focused on comparative effectiveness. In 
these studies, variation in daily clinical practice is used to compare different 
treatments, for example, when different surgeons prefer different treatments 
in the same patient population. To correct for baseline differences between 
treatment groups, we use propensity score matching and mixed models. For 
example, we showed that collagenase clostridium histolyticum in Dupuytren’s 
disease was not significantly different from limited fasciectomy in reducing 
metacarpophalangeal joint contractures in short term outcome, whereas 
proximal interphalangeal joint contractures showed slightly better reduction 
following limited fasciectomy.17 Furthermore, we demonstrated that exercise 
therapy in addition to an orthosis reduces pain more compared to an orthosis 
Figure 4. Screenshot of the personalized patient portal, where patients can learn 
about the treatment, healthcare process, expected outcomes, exercises and can 
also complete the required questionnaires. As soon as a measurement track is as-
signed to a patient, disease-specific information is provided. 
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only in patients with thumb base osteoarthritis16 and that, following a thumb 
carpometacarpal resection arthroplasty, shorter immobilization is non-inferi-
or compared to more prolonged immobilization.13 
In addition to comparative effectiveness, we use our data to develop and 
validate prognostic and clinical prediction models that allow outcome pre-
diction of individual patients, for example on the outcome of non-surgical 
for thumb base osteoarthritis,16,18-20 surgical treatment of primary or recurrent 
carpal tunnel syndrome21-23, and surgery in Dupuytren’s contracture.24,25 
Healthcare context and treatment outcomes 
Figure 5. Screenshot of a physician dashboard, showing the individual patient’s out-
come (magenta line) compared to the ‘average patients’ outcomes (blue line, p50 
and blue area, p25-p75) after a carpal tunnel release. The data shown can be mod-
ified by the user who can select a treatment, a treatment location, and a surgeon. 
These outcomes will then be plotted over the outcomes of all surgeons, treatment 
locations for each treatment.
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We also study how outcomes are not only influenced by treatment but also 
by the process of care delivery and patient experiences. More specifically, we 
consistently found positive associations between patient experiences on care 
delivery and improvement in PROMs following surgical treatments.8,26,27 The 
strongest associations were found for positive experiences with the commu-
nication of the surgeon and providing treatment information, which is in line 
with other studies.8,26,27 
Clinimetric studies 
The collected data also allows evaluating the psychometric measurement 
properties. For example, in patients with Dupuytren’s contracture, we report-
ed that the Patient-Specific Functional Scale (PSFS) is more responsive than 
the more generic and standardized MHQ, despite being much shorter to fill 
in.28 Additionally, we developed decision tree-based versions of the PRWHE29 
and the Boston Carpal Tunnel Questionnaire30 to reduce the number of items 
needed to calculate the total score from 15 and 18 to 6 for both PROMs, with-
out loss of information (see http://handquestionnaires.org).
DISCUSSION
We introduce the design, development, and implementation of a routine 
outcome measurement system in hand and wrist care, describing how our 
data are collected and used for improving clinical care and performing scien-
tific research. The system was feasible by using a highly automated data col-
lection infrastructure, tightly linked to the patient journey and the workflow of 
healthcare professionals. With this paper, we intend to share our experiences 
in designing such a system, our lessons learned, and describe the remaining 
challenges. 
The design and implementation of our routine outcome measurement sys-
tem were facilitated by the specific expertise of the collaborating parties. The 
Erasmus MC, as a large academic center, contributes scientific knowledge 
and Xpert Clinic, as a highly specialized hand and wrist clinic, can quickly 
innovate and integrate the measurements in their workflow. By developing 
dedicated software,9 we could customize the data collection to our specific 
needs and implement changes efficiently. 
Ensuring high compliance of both patients and clinicians remains a chal-
lenge, as in all outcome measurement systems31. We took several measures 
to optimize compliance. A first step was to minimize the measurement bur-
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den and allow direct measurement feedback to both patients and clinicians. 
A second step was to improve data integration during consults and therapy. 
For instance, instead of asking for limitations in daily life during a patient’s 
first visit, clinicians can now see this information beforehand and can discuss 
these issues directly. As a third step, we visualize individual outcomes relative 
to other patients, which provides a reference for both patient and clinician 
to discuss treatment outcomes. At present, we present outcomes as group 
means plus confidence intervals at the level of specific treatments (e.g., a tra-
peziectomy) but this can be further personalized to individuals, e.g., a 70-year 
old female a baseline MHQ score of 50. Hence, in the future, we plan to ex-
tend this and present individualized outcome predictions based on existing 
data. 
Although clinicians value outcome information, more research is needed 
on how to efficiently use outcome data to improve quality of care, while main-
taining practical feasibility. Presently, it remains challenging for clinicians to 
actually use the data in daily practice, due to a variety of reasons such as lack 
of time or inexperience in how to use the data in daily clinical practice. Anoth-
er concern is that a multitude of factors can influence expected outcomes for 
an individual patient which need to be taken into account when discussing 
the expected outcome with a patient. Therefore, we are presently developing 
models that can predict outcome of individual patients. Our current efforts 
are focused on the implementation of these models in daily clinical practice 
so that they can be used in real-time during consultation. In addition, in the 
future, we plan to link outcome data with the cost of treatment as recorded 
in the electronic healthcare record, providing insight into the quality of care 
from a value-based healthcare perspective.
We found that efficient data acquisition software allows outcome record-
ing with a relatively small time investment per patient. Further, at present, the 
main costs include software development and maintenance (approximately 
2-3 fte throughout the last years for all participating treatment centers) and the 
efforts of staff, management and researchers to design the system. By mak-
ing the Gemstracker software open-source and describing our procedures 
in detail, we intend to lower the costs for new centers to develop a similar 
system. However, despite our successful implementation, reimbursement by 
healthcare insurance companies for outcome measurement remains unusu-
al, despite the wish of insurance companies and the government to collect 
outcome data. Hence, further collaboration between healthcare providers, 
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scientists, insurance companies, and governments is needed, since these in-
vestments are currently being made by healthcare organizations themselves.
When comparing the Hand-Wrist Study Group cohort with other large co-
horts and related initiatives, there are significant similarities and differences. 
For example, registries such as the Swedish hand registry32 have larger pa-
tient numbers but less detailed information. Other commonly-used cohorts 
consist of administrative or claim data on hospital, regional, or national level 
(e.g.,33-36). To our knowledge, the present cohort is unique within the field of 
hand and wrist disorders since it contains a large number of patients with 
relatively patients detail of data, covering both outcomes, treatment informa-
tion, and patient characteristics. A limitation, however, is that this cohort is not 
representative of all hand and wrist patients in the Netherlands, for example, 
because complex trauma patients and patients with more severe comorbid-
ities may be treated more often elsewhere. Also, if patients seek treatment 
elsewhere, no follow-up is available. 
For all clinical (e.g., quality evaluation and benchmarking) and scientific 
analysis, missing data are always an important issue. In several of our research 
papers, we have performed extensive missing data analysis and have con-
sistently found that our data can be qualified as missing completely at ran-
dom.37-40 In literature, many statistical analyses and simulation papers have 
indicated that either multiple imputation techniques or analyses that account 
for missing data are superior to complete case analyses.37-41 However, we 
noticed that such techniques are counter-intuitive to many readers. Conse-
quently, we have frequently been asked by journal reviewers to report com-
plete cases, despite that there is literature advising otherwise. 
Since measuring outcomes is central in value-based healthcare,1 it would 
be of great value if more healthcare providers in hand and wrist care would 
routinely measure outcomes. Although there have been several consensus 
initiatives on outcome sets,42-46 none has led to widespread implementation. 
We hope that our example of routine outcome measurement implementa-
tion and the development of the hand and wrist standard set by the Interna-
tional Consortium for Health Outcome Measurement47 will lead to a common 
ground for more widespread comparisons of outcomes. 
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ABSTRACT
Purpose
Previous studies indicate that patients with a more negative perception of 
their illness tend to respond less favorably to treatment, but little is known 
about whether illness perceptions differ based on the type of hand or wrist 
conditions. Therefore, we compared illness perceptions between patients 
scheduled to undergo surgery for four major illnesses in hand surgery: car-
pometacarpal osteoarthritis, Dupuytren’s disease, carpal tunnel syndrome, 
and trigger finger syndrome. We hypothesized there would be differences in 
illness perception between these patient groups.
Methods
Pre-operatively, patients were asked to complete the Brief Illness Perception 
Questionnaire (Brief-IPQ) as part of routine outcome measurement in a spe-
cialized hand and wrist surgery clinic. The Brief-IPQ is a validated question-
naire to rapidly assess the cognitive and emotional representation of illness. 
Differences in illness perception between the four diagnostic groups, correct-
ed for age and sex, hand dominance and work type, were examined. Cohen’s 
D effect sizes were calculated for the between group differences.
Results
We included 514 patients in the analyses: 87 with carpometacarpal osteo-
arthritis, 146 with Dupuytren’s disease, 129 with carpal tunnel syndrome and 
152 with a trigger finger. On a scale ranging from zero (most positive per-
ception) to 80 (most negative perception) the Brief-IPQ sum scores for these 
subgroups were 42.0, 28.2, 38.8 and 33.3, respectively. Corrected for age, 
sex, hand dominance and work type, patients with Dupuytren`s disease had a 
more positive perception of their illness than patients with carpometacarpal 
osteoarthritis and carpal tunnel syndrome. Compared to carpometacarpal 
osteoarthritis patients the effect size for Dupuytren, carpal tunnel syndrome, 
and trigger finger syndrome patients was respectively 1.28, 0.32 and 0.81.
Conclusions
In these patients with various hand/wrist disorders, small to very large dif-
ferences were found in their preoperative perceptions of illness. These dif-
ferences need to be considered during preoperative medical consultations 
and/or when investigating surgical outcomes. Interventions that directly tar-
get negative illness perceptions might improve treatment outcomes for car-




Understanding how patients perceive their illness is important to improve 
treatment outcomes. A negative illness perceptions is associated with de-
creased hand function in patients suffering from chronic osteoarthritis of the 
hand.1 Psychosocial interventions can improve illness perceptions and are as-
sociated with both better treatment outcomes2,3 and increased self-efficacy.4 
Illness perceptions before treatment have shown to be important indepen-
dent predictors of treatment outcome in other medical areas. It is important 
to investigate potential differences in illness perceptions before treatment of 
patients with various hand pathologies. There is only one study that inves-
tigated illness perception in chronic osteoarthritis patients, but a compari-
son across different hand or wrist conditions has not been made. Increasing 
knowledge about differences in illness perceptions between hand surgery 
patients is important to understand which illness perceptions need to be 
addressed in which patient group to ultimately improve outcomes in hand 
surgery. Interventions to modify patients’ illness perceptions may be particu-
larly relevant for those patient groups presenting with more negative illness 
perceptions. 
The common sense model of self-regulation describes how patients per-
ceive their illness and how it relates to patients’ experience of symptoms.5,6 
This model describes a feedback loop in which patients respond to their con-
dition and symptoms by the formation of illness perceptions, which influence 
coping mechanisms and health behaviors (e.g., treatment initiation, treat-
ment adherence). These coping mechanisms and health behaviors will then 
again influence symptom severity. Based on the common sense model, the 
Illness Perceptions Questionnaire (IPQ) was developed to measure patients` 
perception of their illness.7 This questionnaire captures eight domains of ill-
ness perception: 1) ‘consequences’ describes the expected outcome/effects 
of the illness, 2) ‘timeline’ describes how long the patient believes the illness 
will last, 3) ‘personal control’ evaluates beliefs as to how much the patient can 
control the illness, 4) ‘treatment control’ how much the treatment can con-
trol the illness, 5) the domain ‘identity’ describes the extent to which patients 
view experienced symptoms as part of their illness, 6) the ‘concern’ domain 
describes how concerned patients are about their illness, 7) ‘illness compre-
hensibility’ describes how well the patient understands their disease, and 8) 
the ‘emotional representation’ domain is the extent of emotional complaints 
the patient experiences due to the illness.
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The aim of this study was to determine whether patients scheduled for sur-
gery for one of four common hand illnesses (First Carpometacarpal Osteo-
arthritis (CMC-1), Carpal Tunnel Syndrome (CTS), Trigger Finger Syndrome 
(TFS) and Dupuytren’s contracture) differ in their overall and domain specific 
illness perceptions. We hypothesized there would be differences in illness 
perceptions between these groups, even when taking into account possible 
demographic differences between the diagnostic groups.
MATERIALS AND METHODS
Study design
Between September 2017 and November 2017 patients were included 
for this study at our clinic. Our clinic is a specialized center for treatment of 
hand and wrist problems and has 18 different locations, 18 European Board 
certified (FESSH) hand surgeons, and over 150 hand therapists. We includ-
ed all patients who were scheduled to undergo surgery for either: 1) carpo-
metacarpal osteoarthritis (CMC-1 OA), 2) carpal tunnel syndrome (CTS), 3) a 
trigger finger, or 4) Dupuytren’s disease, who gave written informed consent 
and who completed the illness perception questionnaire, as part of routine 
outcome measurements. A clinical diagnosis was made by a certified hand 
surgeon; when considered necessary, a radiograph was taken or electrodi-
agnostic studies were performed to confirm the diagnosis. The study was ap-
proved by the local institutional review board.
MEASUREMENT
Participants completed the Dutch version of the Brief-IPQ8,9 as part of their 
clinical care between the first consultation and one day before surgery. A 
brief demographic questionnaire was completed with a hand therapist after 
the first consultation. Patients received an invitation to complete the IPQ in an 
email. Up to three reminders were sent. The Brief-IPQ is a reliable and validat-
ed measuring tool based on the original and the revised IPQ.7,10 
The Brief-IPQ consists of eight questions to quantify how patients perceive 
their illness across eight different illness perception domains. Patients are 
asked on 10-point scales “how much does your illness affect your life?” (0 = 
no affect at all, 10 = severely affects my life; Consequences domain), “How 
long do you think your illness will continue?” (0 = a very short time, 10 = for-
ever; Timeline domain), “How much control do you feel you have over your 
illness?” (0 = absolutely no control, 10 = extreme amount of control; Personal 
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control domain), “how do you think your treatment can help your illness?” (0 
= not at all, 10 = extremely helpful; Treatment control domain), “how much 
do you experience symptoms from your illness?” (0 = no symptoms at all, 10 
= many severe symptoms; Identity domain), “how concerned are you about 
your illness?” (0 = not at all concerned, 10 = extremely concerned; Concern 
domain), “how well do you feel you understand your illness? (0 = don’t un-
derstand at all, 10 = understand very clearly; Illness comprehensibility do-
main)” and “how much does your illness affect you emotionally?” (0 = not at 
all affected, 10 = extremely affected; Emotional consequences domain). The 
authors of the Brief-IPQ advise to replace the term ‘illness’ in these questions 
with the illness being studied in a particular setting.9 We changed the term 
‘illness’ to ‘hand or wrist illness’ to cover the large variety of patients that are 
treated for different hand or wrist conditions in our clinic. As an indication of 
patient’s overall illness perception, we calculated a sum score after reverse 
scoring the treatment control, personal control and illness comprehensibility 
items, as proposed by the questionnaire developers. The Cronbach’s Alpha 
in our sample was 0.7 indicating an acceptable internal consistency.11 Higher 
scores reflect a  more negative perception of  illness. 
Baseline demographics
To correct for potential confounding, demographic characteristics of all pa-
tients (including age, sex, work type and hand dominance) were collected 
before initiating treatment. 
Statistical analysis
An ANOVA was performed to assess differences between the four diagnos-
tic groups. If the data was not normally distributed, a Kruskal-Wallis test was 
performed. ANCOVA was performed to investigate confounding of potential 
differences in the ANOVA analysis by patient characteristics. A post-hoc anal-
ysis of the ANCOVA using Tukey’s test was performed to compare the illness 
perceptions of the four groups. We performed a post-hoc sensitivity analysis 
to determine the effect size we could detect with our sample. Given a numer-
ator degree of freedom of 18, a power of 0.8 and an alpha of 0.05, we would 
be able to detect an effect size of 0.15 or larger in the ANOVA and an effect 
size of 0.2 or larger in the ANCOVA. For all tests, a p-value ≤ 0.05 was con-
sidered statistically significant. Cohen’s D effect sizes were calculated as the 
differences between the two groups divided by the pooled standard devia-
tion. An effect size between 0.2 and 0.5 was deemed small, between 0.5 and 
0.8 medium, between 0.8 and 1.2 large and bigger than 1.2 as very large.12
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RESULTS
Of 1059 eligible patients, 514 (48%) completed the Brief-IPQ as part of 
routine outcome measurements. There were no significant differences in 
baseline characteristics age, sex, hand dominance and work type between 
patients that did complete the questionnaires and those who did not. Of the 
514 patients who completed the questionnaire, 87 had CMC-1 OA, 146 Du-
puytren’s disease, 152 CTS, and 129 had a trigger finger. Table 1 presents the 
patients demographics of the entire group and each diagnostic group sep-
arately. The CTS group had a significantly lower age and more patients with 
CTS were employed in jobs with average physical intensity of work. There 
were no significant between-group differences on other clinical and demo-
graphic variables. 
There was a significant difference between groups in overall IPQ scores 
(p<0.05). After adjusting for age, sex, workload and whether the dominant 
hand was operated, ANCOVA still showed a significant difference between 
the overall IPQ scores of the four groups (F(3.351) = 20.48, p<0.05. CMC-
1 patients had the most negative illness perception followed by Dupuytren, 
CTS, and TFS patients (see Table 1). Compared to carpometacarpal osteo-
arthritis patients the effect size for Dupuytren, CTS, and TFS patients was re-
spectively 1.28, 0.32 and 0.81.
All patients had a similar strong positive belief in the treatment, as well as 
low personal control (see Figure 1). On the consequences, timeline, identity, 
concern, illness comprehensibility and emotional representation scales there 
were significant differences between the groups (Table 1). These differences 
remained significant after adjusting for age, gender, workload and whether 
the dominant hand was operated. The general pattern for these subscales 
was that patients with CMC-1 OA had the worst illness perception, followed 
by CTS and TFS. An exception was the timeline domain, where patients with 
Dupuytren’s disease and CMC-1 OA had worst perception of timeline, see 
Figure 1.
Table 2 presents the post-hoc analysis of the ANOVA of the differences in 
IPQ subscale scores between the groups. The largest significant differences 
were found between CMC-1 OA and Dupuytren’s disease on the consequenc-
es and identity scales, i.e. patients with CMC-1 OA scored 3.9 and 3.2 points 
higher (i.e. less favorable perception), respectively, compared to patients with 
Dupuytren’s disease. Moreover, the only significant difference between the 
CMC-1 OA and CTS groups was on the timeline scale and the sum score, i.e. 
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Table 1. Baseline patient characteristics and Illness Perception Questionnaire (IPQ) 
domains for all patients and for the diagnostic groups separately. Higher values of 











  N = 514 N = 87 N = 146 N = 152 N = 129
Age in years, 
mean (sd) 58.6 (12.4)* 60.0 (8.5) 62.5 (9.1) 54.24 (14.8) 58.5 (12.9)
Sex (% female) 53 † 76 23 73 62
Dominant hand 
treated (%) 57 † 46 49 64 64
Work type (%)          
No work 42 † 49 49 32 40
Light work 23 † 13 22 35 24
Average work 26 † 23 15 38 27
Heavy work 9 15 7 9 9
Brief IPQ-subscale, 
mean (sd)          
Consequences1 5.8 (2.8)* 7.5 (1.6) 3.5 (2.7) 6.8 (2.3) 6.1 (2.6)
Timeline1 5.6 (2.9)* 6.7 (2.3) 6.1 (3.4) 5.5 (2.6) 4.2 (2.6)
Personal control2 4.0 (2.8) 4.2 (2.5) 3.8 (3.2) 4.1 (2.6) 4.2 (2.7)
Treatment control2 8.4 (1.4) 8.3 (1.2) 8.3 (1.4) 8.5 (1.4) 8.6 (1.5)
Identity 1 5.6 (2.8)* 6.9 (2.2) 3.7 (2.7) 6.6 (2.4) 5.6 (2.7)
Concern1 5.1 (2.9)* 6.5 (2.5) 3.5 (2.6) 5.8 (2.8) 4.8 (2.9)
Illness comprehen-
sibility2 8.3 (2.0)* 8.4 (1.9) 8.6 (1.6) 8.0 (2.0) 8.2 (2.3)
Emotions1 3.7 (3.0)* 5.2 (2.8) 2.1 (2.5) 4.5 (3.0) 3.4 (2.8)
Sum score 
(range: 0-80) 34.9 (12.1)* 42.0 (9.6) 28.2 (11.8) 38.8 (10.1) 33.3 (11.7)
CTS, carpal tunnel syndrome; CMC-1 OA, carpometacarpal osteoarthritis; sd, standard deviation
* indicates p < 0.05 using an ANOVA
† indicates p < 0.05 using a chi-squared test
¹ indicates a range from 0 to 10, where a higher value corresponds with a more negative illness perception
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patients with CMC-1 OA scored 1.2 and 3.7 points higher, respectively, than 
patients with CTS. 
Furthermore, post-hoc analysis of the ANCOVA (Table 3) showed that only 
patients with Dupuytren’s disease had a significantly more positive illness 
perception than the other three groups. The only other significant differenc-
es were between CMC-1 OA and CTS on the emotional representation and 
timeline scale, i.e. patients with CMC-1 OA scored 1.1 and 1.1 points higher, 
respectively, than patients with CTS. 
DISCUSSION
This study compared preoperative illness perceptions in patients scheduled 
for surgery for CMC-1 OA, Dupuytren’s disease, CTS or TFS. Patients with 
CMC-1 OA have a more negative perception of their illness, whereas patients 
with Dupuytren’s disease have a more positive perception of their illness. This 
difference was mainly driven by: i) consequences patients experienced from 
the disease, ii) to what extent patient viewed the experienced symptoms as 
part of their illness, iii) their concern about the illness, and iv) emotional con-
sequence of the illness.   
These findings suggest that preoperative interventions focused on chang-
ing illness perceptions may not be necessary for patients with Dupuytren’s, 
but may be helpful for patients with CMC-1 and CTS. A meta-analysis of ill-
ness perception13 has shown that individuals with various medical illnesses 
and similar illness perceptions to patients with CMC-1 and CTS have impaired 
physical functioning, psychological wellbeing and social functioning.14-17 Re-
search also shows that psychosocial interventions can change illness percep-
tion and thus improve treatment outcomes across a variety of medical con-
ditions.18,19 Such psychosocial interventions focus on patients’ perceptions of 
the consequences of their disease and the manner in which they label and 
interpret their symptoms and disease. For example, in patients with coronary 
heart disease, interventions that i) educated patients about their illness, ii) 
changed nonadaptive or incorrect perceptions, or iii) taught patients how to 
cope with their illness, were effective to change patients illness perceptions.20 
This is in line with the current opinion about the added value of psychosocial 
interventions on outcomes in hand surgery.21 
We also found between group similarities regarding the amount of per-
ceived control over the illness. Although patients in these four groups may 
have different underlying pathologies, they all had similarly low levels of per-
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sonal and high levels of treatment control, as well as similarly high levels of 
perceived understanding of their illness. This pattern is similar to what has 
been reported for patients undergoing total hip or knee replacement sur-
gery.22 Such patterns of low perceived personal control on the one hand, and 
high treatment control and understanding of the disease on the other hand, 
might be typical for patients scheduled for elective surgery. 
Especially low personal control could have a negative influence on the 
outcome and might therefore be a viable target for intervention. Low per-
sonal control has been shown to be associated with worse adherence to 
treatment23,24 and worse outcomes.25,26 For example, Hsiao et al showed that 
patients with positive illness perceptions adhered better to anti-hypertension 
medication than patients with negative illness perceptions. If this association 
of adherence also extends to post-operative rehabilitation, this represents 
an opportunity for educational or psychosocial interventions. This could be 
achieved by helping patients understand that, after surgery, the outcome of 
their recovery is co-dependent on their motivation and adherence to post-op-
erative rehabilitation protocols.27 By helping patients to reconsider their per-
ceived lack of personal control, we may improve treatment outcome. 
A limitation of our study is the non-responder rate. Of all patients who were 
scheduled for surgery during the study period, 52% did not complete the 
Brief-IPQ. However, non-response was not dependent on any of the baseline 
characteristic (age, sex, hand dominance and work type; data not shown). 
Thus, we believe that these factors did not influence the conclusions of this 
study.
Several factors may have influenced the results acquired via the Brief-IPQ. 
First, all questionnaires were collected after patients had received their di-
agnosis during initial consultation and were scheduled for surgery; this may 
have had an impact on how they perceived their illness. Consulting with a sur-
geon can influence the perception of the illness. Any misconception the pa-
tient had before the consultation might be addressed by the surgeon during 
the consultation. Second, for most patients this was the first time that their 
illness was labeled as ‘something to be treated’ and the need for surgery it-
self might make the illness seem more threatening; both these aspects may 
have influenced the patient’s perception of illness. Third, differences between 
treatment locations may result in different illness perception. However, post 
hoc analyses revealed that there was little variance in illness perceptions that 
could be explained by location (ICC = 0.03; not further reported). Fourth, we 
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know that patients with Dupuytren’s disease have no pre-operative pain28,29 
and that CMC-1 OA is characterized by pain.30 While we could not test this 
in the present study, it is possible that pain influences illness perceptions of 
hand surgery patients, and this should be assessed in future studies. Fifth, 
differences in other psychosocial factors such as anxiety and depression, as 
described by Beleckas et al. could influence patients perception of illness.31 
Finally, patients referred to a highly specialized hand clinic, such as our clinic, 
might perceive their illness as being more severe as compared to patients 
referred to a less specialized clinic. All these factors exist in daily practice and 
will likely influence, to some extent, illness perception in daily practice. There-
fore, our findings can only be generalized to situations where illness percep-
tions are evaluated under similar circumstances. 
The results of this study have important clinical implications by drawing at-
tention to the differences in illness perception among individuals who under-
go four common hand and wrist conditions. By being aware of an individual’s 
illness perception along with the type of surgery they will receive, surgeons 
can directly target the particular aspects of illness perception through educa-
tional information and the language they use (i.e. avoiding language that may 
amplify negative illness perceptions). In some cases, in which illness percep-
tion is negative, psychosocial interventions focused on increasing resiliency 
may be helpful. Given that the four surgical procedures are elective, undergo-
ing skills training to improve illness perception may be feasible, particularly 
when recommended by surgeons, along with educational information about 
optimized recovery and outcome of surgery. 
Future studies should focus on how illness perceptions of patients sched-
uled for hand surgery relate to treatment outcomes, how illness perceptions 
relate to specific types of coping, and how interventions on illness percep-
tions affect outcomes. For example, in patients suffering from CMC-1 OA, 
evaluating the association between illness perception and outcome might 
provide more preoperative information on the expected outcome and en-
able surgeons to better inform patients about their expected outcome. Fur-
thermore, evaluating how these patients cope with pain may provide more 
insight into the role of illness perceptions in coping with the outcomes of 
disease, which can provide a framework to guide patients during treatment 
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Dupuytren’s disease: more than extension deficit
ABSTRACT
This prospective study investigates the extent to which a better experience 
with healthcare delivery is associated with better postoperative treatment 
outcomes after surgery for Dupuytren’s contracture. Patients undergoing lim-
ited fasciectomy or percutaneous needle fasciotomy for Dupuytren’s contrac-
tures completed the Michigan Hand Outcomes Questionnaire before and 3 
months after surgery, together with a patient reported experience measure, 
while hand therapists assessed the straightness of the finger with a goniom-
eter. Regression analyses were used to examine associations. We found that 
a better experience with healthcare delivery was associated with better pa-
tient-reported outcomes, while association with residual extension deficit was 
minimal. Strongest associations were seen with communication of the phy-
sician, postoperative care and information about the treatment. Experience 
with the treatment explained up to 12% of the variance in treatment outcome. 
These findings suggest that patient reported treatment outcomes in Dupuy-




In modern practice both physical treatment outcomes and patient-report-
ed outcome measures (PROMs) are used to evaluate health outcomes after 
treatment. Most recently, patient-reported experience measures (PREMs) 
were added to this evaluation.1,2 Patient-reported experience measures  fo-
cus on aspects such as respect and dignity, communication by physicians and 
cleanliness or hygiene of facilities, and can be used to routinely measure and 
quantify different aspects of treatment context or experience with healthcare 
delivery.3 Besides being useful in the evaluation of treatment, PREMs can be 
useful in clarifying the relation between experiences with healthcare deliv-
ery and treatment outcomes. Several observational studies have shown that 
a better experience with healthcare delivery is associated with better patient 
reported outcomes.4 Although these observational studies do not provide 
causal evidence for this relationship, recent meta-analyses of randomized 
clinical trials have shown that influencing the context, for instance by improv-
ing the communication between patient and clinician, directly improves the 
patient-reported health status.5,6 
Despite being deemed important7, these relationships have not yet been 
studied in Dupuytren’s disease nor in hand surgery all together. Therefore, 
the objective of this prospective study was to investigate the extent to which 
a better experience with healthcare delivery is associated with better post-op-
erative treatment outcomes after surgery for Dupuytren’s contracture, as as-
sessed by both a patient-reported outcome measurement as well as remain-
ing extension deficit in the finger recorded by a therapist.
METHODS
Study design
Patients who underwent either limited fasciectomy (LF) or percutaneous 
needle fasciotomy for Dupuytren’s contractures between February 2011 
and December 2016 at a consortium of 16 hand surgery practice sites in the 
Netherlands were selected from a prospectively maintained database that 
was designed for clinical and research purposes. Patients who had complet-
ed a post-operative PROM and PREM and had finger goniometry recorded 
were included in the final analysis (Figure 1).  All patients provided written 
informed consent for the use of their data. As part of routine outcome mea-
surement, patients were invited to complete a PROM questionnaire prior to 
surgery and both a PROM and PREM questionnaire three months afterwards. 
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Two reminders were mailed to non-responders. Patient and disease-specific 
characteristics derived from this database were age, sex, occupational status, 
comorbidities, current tobacco and alcohol use, family history of Dupuytren’s 
disease, hand dominance and post-operative degree of contracture.
PROM
Patients completed the Michigan Hand Outcomes Questionnaire (MHQ).8 
This rigorously developed, hand-specific PROM assesses six domains of hand 













Residual extension deficit 
N = 836




No residual extension 
deficit measurements 
N = 556
Figure 1. Flowchart of subject inclusion
PROM, Patient reported outcome measures; PREM, Patient reported 
experience measures
Figure 1. Flowchart of subject inclusion.
PROM, Patient reported outcome measures; PREM, Patient reported experience measures
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pain, aesthetics and patient satisfaction with hand function. All questions are 
answered by means of a five-point Likert scale. Domain- and total scores, 
ranging from 0 (poorest function) to 100 (best function), were calculated ac-
cording to the questionnaire developer’s instructions.8 As most of the patients 
in our population were either unemployed or retired, the domain on work 
performance was not included in this study. Only the scores pertaining to the 
treated side were used. As a measure of treatment effectiveness, the change 
between the pre- and post-operative PROM for each patient was calculated.
PREM
Patients completed a widely used PREM questionnaire in private practice 
clinics in The Netherlands. This questionnaire aims at measuring the patient’s 
experience with the clinic, marketing position of the clinic and logistics with-
in a clinic. For the current analysis, 25 items concerning the patient’s experi-
ence were used. With help of an exploratory factor analysis six subscales were 
identified: physician communication and competence (six items); peri-oper-
ative care (four items); post-operative care (four items); general information 
(two items); treatment information (three items); quality of facilities (six items) 
(See appendix, Online Supplementary Material, which contains the questions 
used in the PREM questionnaire). The subscale regarding peri-operative care 
was reduced to two items for patients undergoing needle fasciotomy, drop-
ping the items concerning the anaesthetist, as this procedure is done under 
local anesthesia administered by the hand surgeon. 
Each item pertaining to one of the six domains of healthcare delivery, was 
graded by the patient according to the Dutch academic grading system con-
sisting of a ten point scale where one represents a very poor result, and ten 
an excellent result. When a question did not apply to a patient, for example, 
if they did not use the website, there was a possibility to answer so. Scores on 
different subscales were determined as the mean of the items on that sub-
scale. 
Internal consistency in our sample, assessed using Cronbach’s α, was: physi-
cian communication and competence 0.95; peri-operative care 0.83 (for nee-
dle fasciotomy patients 0.62); post-operative care 0.89; general information 
0.84; treatment information 0.87; quality of facilities 0.87.
Residual extension deficit
The degree of total residual contracture was assessed by certified hand 
therapists during visits occurring between six and twelve weeks after treat-
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ment by calculating the sum of the degree of active extension deficit at the 
metacarpophalangeal, proximal interphalangeal, and distal interphalangeal 
joint levels. Any hyperextension was converted to 0 degrees at an individual 
joint level to prevent underestimation of the total degree of extension deficit. 
When multiple digits were affected, we used the measurements pertaining to 
the most severely contracted digit at follow-up. 
Missing data 
Diabetes, smoking- and alcohol status was unknown in 18% of the patients. 
In the PREM questionnaire there was missing data in the ‘post-operative care’, 
‘general information’ and ‘peri-operative care’ subscales of, respectively, 17%, 
21% and 29%. In the three remaining PREM-subscales the missing data was 
less than one percent. Subscales with missing data were not calculated, as 
most of the missing data was accounted for by patients answering that a 
question did not apply to them. 
Statistical Analyses
Significance testing was done by means of a Student’s t test for normally dis-
tributed data, a Wilcoxon rank-sum test for non-normally distributed data and 
a chi-squared test for categorical data. Distribution of the data was evaluated 
with histograms and QQ norm plots. To assess the potential of selection bias, 
we compared baseline patient characteristics between patients who met the 
inclusion criteria and those who did not. 
To assess the relationship between PREM scores and PROM change scores 
and residual extension deficit, linear regression analyses were used. Beta-co-
efficients were used to determine the effect size of each PREM-subscale. As 
the measurement error for goniometry is commonly accepted to be roughly 
three to five degrees per joint9, an effect size of smaller than ten degrees 
for the residual extension deficit (all joints summed up) was regarded as not 
clinically relevant. To determine to what extent the variation in treatment out-
come between patients could be explained by the experience with health-
care delivery, all six PREM-subscales were introduced simultaneously in the 
same model as independent variables. Multivariable regression models were 





A total of 836 patients met the inclusion criteria. Patients who met the inclu-
sion criteria  underwent more limited fasciectomies and had a slightly better 
patient reported outcome compared to those who did not meet the inclusion 
criteria. Patient and disease-specific characteristics that were derived from the 
database are shown in table 1. The change between pre- and post-opera-
tive PROM scores was significant across all subscales (Table 2). The different 
PREM-subscores and residual extension deficit are shown in table 2. 
For the univariate relation between the PREM score and the PROM score, 
we found significant positive associations between patients’ PREM score and 
the change in their PROM  score on all subscales, with the exception of the 
association between the quality of the facilities and the aesthetics subscale of 
the MHQ (Table 3). For example, an improvement of one point in the physi-
cian 1-10 PREM-scale was associated with an increase of 3.7 points of the to-
tal 0-100 PROM-score. The strongest associations with a better PROM change 
score were seen in ‘physician communication and competence’, ‘post-oper-
ative care’ and ‘treatment information’, which can be determined from the 
standardized associations. PREM-subscales explained 3-12% of the variation 
in MHQ-subscales (bottom row Table 3).
Similarly, for the univariate relation between the PREM score and residual 
contraction, we found positive associations between all PREM-subscores and 
straightness of the finger (i.e. a lower residual extension deficit), with only the 
association between the quality of the facilities and residual contraction not 
being significant (Table 3). For example, an increase of one point in the phy-
sician PREM-scale was associated with a decrease of 2.1 degrees in residual 
extension deficit. However, none of the effect sizes for the residual extension 
deficit was larger than ten degrees and were therefore not clinically relevant.
Adjusting for potential confounders had little effect on the size of the asso-
ciations, with only two associations being no longer significant, both of which 
had borderline significance before adjusting for potential confounders (Table 
4). Most notably, recurrent disease and the type of surgery had no influence 
on the associations. Addition of these patient- and disease characteristics 
added an additional 4-8% to the explained variance (bottom row Table 4). 
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Table 1. Baseline characteristics of included vs. not included patients.
Included Not included p-value
N = 836 N = 1859
Age in years, mean (sd) 63.4 (8.4) 62.4 (9.6) 0.01
Sex (% male) 74.8 73.9 0.69
Smoking (%) 13.2* 17.0 0.03
Alcohol (%) 81.5* 79.6 0.34
Diabetes (%) 8.8* 10.4 0.31
Positive family history (%) 48.9 49.2 0.92
Occupational intensity (%) 0.03
Unemployed/retired 56.2 50.8
Light (e.g. office work) 27.4 30.1
Medium (e.g. cleaning) 11.7 12.3
Heavy (e.g. construction work) 4.7 6.8
Surgery on dominant hand (%) 51.7 53.5 0.40
Type of surgery (%) <0.01
Limited fasciectomy 82.5 74.9
Needle fasciotomy 17.5 25.1
MHQ – baseline, mean (sd)
General hand function 67 (16) 67 (17) 0.79
ADL 90 (14) 88 (16) 0.19
Pain 77(20) 74 (22) 0.003
Aesthetics 71 (20) 70 (21) 0.77
Satisfaction 67 (24) 65 (25) 0.19
Total 76 (14) 75 (16) 0.046
MHQ, Michigan Hand Outcome Questionnaire; ADL, Activities of Daily Life
* N = 688
DISCUSSION
In this study, we found that patients with Dupuytren’s contractures who re-
ported more positive experiences with the way their care was delivered, also 
showed more positive treatment outcomes. Confounding factors including 
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Table 2. Outcome measurements of included patients (N = 836)
Pre-operative Post-operative
PREM - scores, median (IQR)
Physician: communication & competence 8.2 (7.8-9.0)
Peri-operative care (N = 595) 8.5 (8.0-9.0)
Post-operative care (N = 696) 8.3 (8.0-9.0)
General information (N = 660) 8.0 (8.0-9.0)
Treatment information 8.0 (7.7-9.0)
Quality of facilities 8.3 (7.8-9.0)
MHQ - scores, mean (sd)
General hand function 67 (16) 73 (16)*
ADL 90 (14) 92 (12)*
Pain 77 (20) 80 (19)*
Aesthetics 71 (20) 84 (19)*
Satisfaction 67 (24) 82 (20)*
Total 76 (14) 83 (13)*
Residual extension deficit – degrees,
median (IQR) 16 (6.8-27.3)
MHQ, Michigan Hand Outcome Questionnaire; PREM, Patient Reported Experience Measure; ADL Activities 
of Daily Life; IQR, InterQuartile Range; sd, standard deviation
* difference pre- and post-operative with p<0.01
patient- and disease-specific characteristics, most notably, recurrent disease, 
had a limited effect. Thus previous experience with surgery for Dupuytren’s 
disease, and the type of surgery did not influence the associations. While 
treatment context had a relatively large effect on patient-reported outcomes, 
the association with physical treatment outcomes was very small and may not 
be considered clinically relevant. These findings imply that the context of a 
surgical treatment for Dupuytren’s disease has a greater effect on the patient’s 
perceived outcomes than on physical treatment outcome measurements.
In general, the domains of ‘physician communication and competence’, 
‘post-operative care’ and ‘treatment information’ had the strongest asso-
ciation with a more positive treatment outcome. This finding is in line with 
previous studies which reported that patient experience with the physician’s 
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outcome.4,10,11 In addition, our results show that a good experience with  the 
treatment information provided was also strongly associated with patient-re-
ported treatment effectiveness. Overall, treatment context explained 11.6% 
of the variation of the total MHQ-score. Addition of patient- and disease 
characteristics as well as surgery type only added an additional 4% to the ex-
plained variance of the total MHQ-score. These results suggest that treatment 
context, rather than patient- and disease characteristics or the type of surgery, 
played a large role in predicting patient-reported outcomes in Dupuytren’s.
A possible explanation for these results could be that good communication 
and good treatment information results in better or more realistic expecta-
tions of the outcome. 
Expectations are seen as a crucial ingredient of placebo-like effects.12 It has 
been shown that expectation can be modulated by using an empathetic in-
teraction style13 or by discussing patient’s treatment believes14, which in turn 
can have a beneficial effect on treatment.15,16
Besides the role of optimized expectations, a more positive evaluation of the 
physician might also reflect a more trustful physician-patient relationship.17 
In turn, this might lead to better treatment adherence and arguably better 
treatment outcomes.18,19 However, it is also possible that patients with a bet-
ter outcome will report a better experience, as they may be more inclined to 
accept shortcomings in their experience with the given care. In the absence 
of an interventional study, a definitive conclusion about the direction of this 
association between treatment context and health outcome cannot be made.
The main strengths of this study are the use of both patient-reported and 
physical outcome parameters, prospective collection of the data and the 
large sample size collected across the Netherlands. The relative large loss 
to follow-up (69%) is a limitation of this study, which may have led to under- 
or overestimation of the identified associations. However, our analyses did 
not show clinically relevant differences in baseline characteristics between 
patients who were included or excluded, reducing the likelihood of biased 
results. It is uncertain if the results are generalizable to other hand disorders. 
In Dupuytren’s disease, pain is not as prominent as in, for example, arthrosis. 
This might result in different associations, as patients with pain have different 
reasons to seek medical help and therefore different expectations from their 
treatment.20 With regard to the patient-reported experience, the question-
naire used in this study is not as thoroughly developed and tested as some of 
the other experience questionnaires.21 Nevertheless, the subscales showed 
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good internal consistency. 
In conclusion, this study shows that a better experience with healthcare de-
livery is associated with a better treatment outcome in the treatment of Dupu-
ytren’s disease.  Optimizing experience with health care delivery may provide 
a new and relatively unexplored pathway for improving healthcare outcomes 
in hand surgery. 
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ABSTRACT
Background
Patient reported outcome measures have become the standard tool for re-
flecting the patient’s perspective on their functioning and treatment outcome 
for a wide variety of hand conditions. One such measure, the Patient-Specific 
Functional Scale (PSFS), is an individualized questionnaire that enables pa-
tients to specify those activities with which they have difficulty in daily life. 
Purpose
This study aims to determine the content validity and responsiveness of the 
PSFS compared with the Michigan Hand Questionnaire in patients with Du-
puytren’s disease. 
Methods
Patients with Dupuytren’s disease being treated with percutaneous needle 
aponeurotomy, limited fasciectomy or skin graft were selected from a data-
base with routine outcome measurements. These measurements were per-
formed as part of usual care prior to and three months after treatment. In 
order to assess content validity of the PSFS, the activities specified by patients 
were classified into the International Classification of Function core set for 
hand conditions. The Standardized Response Mean is calculated for the pre-, 
post change scores of the PSFS to evaluate responsiveness.
Results
308 patients were analysed prior and three months after treatment. Content 
validity of the PSFS was appropriate since 95% of all items could be classi-
fied into the International Classification of Function activities and participation 
domain. The Standardized Response Mean of the PSFS was 1.0 (95% confi-
dence interval 0.86-1.2), which was substantially larger than the Standardized 
Response Mean of the Michigan Hand Questionnaire score 0.58 (95% confi-
dence interval 0.42-0.74). 
Conclusions
Our results indicate that the PSFS scale is a content-valid questionnaire 
which may be more responsive to change than a fixed-item instrument like 
the Michigan Hand Questionnaire in patients with Dupuytren’s disease, mak-
ing it a valuable additional instrument to highlight therapy goals and evaluate 
the progress over time in a patient with Dupuytren’s disease. 
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INTRODUCTION
Patient-centred care is the practice of caring for patients in ways that are 
meaningful and valuable to the individual patient.1 In recent years patient 
reported outcomes measures have become the standard measurement for 
reflecting the patient’s perspective for a wide variety of hand conditions. 
Standardized patient reported outcomes measures such as the Disabili-
ties of the Arm, Shoulder and Hand Questionnaire (DASH), Michigan Hand 
Questionnaire (MHQ) and Patient Rated Wrist and Hand Evaluation (PRWHE) 
use predefined questions to assess hand function. These fixed-item question-
naires allow comparing patient groups and treatment methods and support 
the development of evidence-based practice. However, the predefined na-
ture of these fixed-item patient reported outcomes measures may limit the 
capability to capture the unique needs and difficulties of each individual pa-
tient, especially for those conditions where patients experience a wide variety 
of problems2. Individualized patient reported outcomes measures enable pa-
tients to specify activities with which they have difficulty in their daily life. Such 
patient specific questionnaires may provide a valuable addition to fixed-item 
patient reported outcomes measures to capture individual functional prob-
lems encountered by patients with Dupuytren’s disease.3-6 As each activity is 
self-generated by the patient, the scale is patient-specific and thus fits well 
with the current emphasis on the patient being the focus of healthcare. In 
addition, a patient-specific questionnaire may be more responsive to change 
than standardized fixed-item patient reported outcomes measures.2 
Several individualized patient reported outcomes measures exist, such as 
the Measure Yourself Medical Outcome Profile (MYMOP)7, Canadian Occu-
pational Performance Measure (COPM)8 and the Patient-Specific Functional 
Scale (PSFS).10 In the field of hand therapy, the PSFS is the most common-
ly used individualized patient reported outcomes measure.10 The COPM is 
based on a semi-structured interview and although previous studies have 
shown the potential benefit of the COPM in patients with Dupuytren’s dis-
ease4, it is time-consuming to administer the COPM in clinical practice. In con-
trast, the PSFS is an easy and relative quick tool where patients identify and 
score up to five activities affected by their condition. The PSFS was reported 
valid, reliable and responsive in conditions such as knee dysfunction, cervical 
radiculopathy and acute low back pain.11 While the individualized aspect and 
ease of the PSFS may be promising, its use in patients with Dupuytren’s dis-
ease has not yet been studied. Therefore, the aim of this study is to establish 
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the content validity of the PSFS in our sample and determine which of the 
most frequently-mentioned functional problems in the PSFS are evaluated 
in the fixed-item patient reported outcomes measures (DASH, MHQ, PRWHE 
and URAM). Moreover, the responsiveness of the PSFS in patients with Du-
puytren’s disease, i.e. its ability to detect change, is assessed and compared 
with the MHQ. 
METHODS
Study design
This multicentre inception cohort includes all patients being treated for 
Dupuytren’s disease with percutaneous needle aponeurotomy, limited fas-
ciectomy or skin graft between October 2014 and September 2015 in seven 
hand surgery practice sites. Patients were selected from a database which 
contained routine outcome measurements.12 Measurements were performed 
as part of usual care prior to and three months after treatment. We restricted 
our analyses in this study to patients with available preoperative data on the 
PSFS questionnaire and we did not exclude patients based on patient char-
acteristics, clinical success or failure. All patients provided written informed 
consent for the use of their data. The study protocol was approved by the 
institutional review board of the Erasmus Medical Centre. Patient characteris-
tics derived from this database included age, sex, diabetes, smoking, employ-
ment, recurrent disease and family history. 
Outcome Measurements
Patient Specific Outcome Scale (PSFS)
In the PSFS, patients identify and score three to five important activities that 
they are unable to perform or have difficulty with as a result of their condi-
tion9. More specifically, before treatment, a hand therapist asked the patient: 
“I am going to ask you to identify up to five important activities that you are 
unable to do or are having difficulty with as a result of your hand problem. Are 
there any activities that you are unable to do or having difficulty with because 
of your hand problem?” Activities were scored on an 11-point scale with ‘0’ 
representing ‘unable to perform’ and ‘10’ representing ‘able to perform at 
prior-disease level’. At follow-up, the patients are presented with the same 
activities again and ask to rate the ability for each activity. The total PSFS score 
is the average score of all activities produced by the patient. 
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Michigan Hand Outcome Questionnaire (MHQ)
The MHQ is a hand-specific questionnaire with six domains: ‘hand function’, 
‘activities of daily living’ (ADL), ‘work performance’, ‘pain’, ‘aesthetics’ and ‘pa-
tient satisfaction with hand function’. All questions are answered on a five-
point Likert scale. Domain and total scores, all ranging from 0 to 100, were 
calculated according to the instructions.13 Higher scores indicate better hand 
performance. The MHQ is a valid and reliable measurement instrument for 
several hand problems.13 The Dutch Language Version of the MHQ is used 
in this study.15
Total Active Extension Deficit (TAED)
The TAED of the affected fingers was assessed by hand therapists prior to 
treatment and 6 to 12 weeks after treatment by calculating the sum of the de-
gree of active extension deficit at the metacarpophalangeal, proximal inter-
phalangeal, and distal interphalangeal joint levels. Any hyperextension was 
converted to 0 degrees at an individual joint level to prevent underestimation 
of the total degree of extension deficit. Patients are asked to active extend the 
finger as much as possible and the range of motion in measured with a goni-
ometer on the dorsal aspect of the finger. The dorsal measurement method 
with good alignment of the goniometer has been reported to be a reliable 
measurement method to assess active range of motion of the finger.16 Mea-
surements were recorded to an accuracy of one degree. When multiple fin-
gers were affected, we used the measurements of the most severely contract-
ed finger at baseline. 
Content validation
The PSFS aims to evaluate patient-specific problems in the ‘activities and 
participation’ component of the International Classification of Function (ICF) 
scale. Activity limitations are defined as difficulties an individual may have in 
executing activities in daily life. Participation restrictions are problems that an 
individual may experience in involvement in life situations.17 Appropriate con-
tent validity is reached if 90% of all reported items on the PSFS can be classi-
fied in the ‘activities or participation’ domain of the ICF scale.18,19 To analyse 
which functional problems patients with Dupuytren’s disease were mentioned 
in the PSFS, we used the Comprehensive ICF Core Set for Hand Conditions 
as a framework. This framework is developed as a basis for studying content 
validity of already existing instruments.20 Two authors (Yvk and KG) inde-
pendently classified all problems as reported by patients on the PSFS within 
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the Comprehensive Core Set for Hand Conditions. Items that were differently 
classified by the two authors were discussed until consensus was reached. 
Thereafter, we evaluated to what extent the ten most frequently-mentioned 
functional problems in the PSFS are present in the Unité Rhumatologique des 
Affections de la Main (URAM), DASH, PRHWE and MHQ questionnaires. 
Responsiveness to change 
Patients with pre- and post-operative measurements were compared using 
a paired t-test for normally distributed data and the Wilcoxon signed-rank test 
for non-normally distributed data. Data distribution was analysed using histo-
grams and QQ norm plots. Sensitivity analyses were performed to compare 
baseline characteristics of patients who completed both the PSFS and MHQ 
at follow-up and those patients who did not. Significance thresholds were set 
at p ≤ 0.05. To compare the responsiveness to change of the PSFS and MHQ 
the Standardized Response Mean (SRM) for paired data with 95% bias-cor-
rected bootstrap confidence intervals were calculated. The SRM is calculated 
as the mean change score divided by the standard deviation of the change 
score and were considered significantly different if confidence intervals did 
not overlap. SRM smaller than 0.20 was considered small, up to 0.50 mod-
erate and SRM higher than 0.80 was considered large.21 Based on the fact 
that the MHQ may miss items that are important for the individual patient, 
we hypothesized that there would be greater improvement 3 months after 
surgery in the scores of the PSFS (SRM> 0.80) compared with the functional 
scales ‘Hand Function’ and ‘ADL’ of the MHQ and the total MHQ score (SRM< 
0.50). Floor- and ceiling effects were defined as at least 15% of the patients 
achieving the best or worst level of the questionnaire score.22
RESULTS
325 patients with Dupuytren’s disease were eligible for this study. One pa-
tient was excluded because the PSFS items were accidentally changed during 
the post-operative evaluation. Sixteen patients could not mention a single 
functional problem. These patients were included for the content validation, 
but not for the analysis of responsiveness to change. The mean age was 63 
(SD 9) years and 76% underwent a limited fasciectomy (Table 1). 
A total of 943 items in 42 different dimensions of the Comprehensive Core 
Set for Hand Conditions were mentioned in the PSFS. Almost all (95%) of 
these items could be classified in the ‘activities and participation’ domain of 
the ICF. The remaining five percent were classified in the ICF ‘function’ do-
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main, including items such as ‘stiffness’ and ‘strength’. The majority of the 
functional problems could be classified in the ‘recreation and leisure’ do-
main (Table 2), including, sports, playing a music instrument and gardening. 
The second most commonly mentioned items were functional problems like 
‘pushing yourself up’ or ‘lean on your hand’. Furthermore, the PSFS identified 
very specific problems such as ‘to put on a glove’, ‘hand in pocket’, or ‘com-
puter use’; activities that are not evaluated on the DASH, PRWHE, MHQ or 
URAM questionnaire.
197 patients completed both the PSFS and MHQ at baseline and follow-up. 
Sensitivity analyses showed no baseline differences between patients who 
completed both questionnaires and those who did not (Table 3). The mean 
PSFS score improved significantly from 5.0 (SD 2.2) at baseline to 7.7 (SD 2.1) 
at follow-up. Similarly, all MHQ subscales, except the ‘work’-subscale, showed 
significant improvement (Table 4). The TAED improved from 67 degrees prior 
to surgery to 20 degrees after surgery. The SRM of the PSFS was 1.0 (95% con-
Table 1. Patient characteristics (N = 308)
Age in years, mean (sd) 63 (9)
Sex (% male) 71
Surgery on dominant hand (%) 49
Positive family history (%) 46
Occupational situation (%)
Unemployed/retired 53
Light (e.g. office work) 27
Medium (e.g. cleaning) 14
Heavy (e.g. construction work) 6
Type of surgery (%)
Limited fasciectomy 76
Needle fasciotomy 20
Limited fasciectomy & skin graft 3
Needle fasciotomy & lipofilling <1
Recurrent disease (%) 29
Duration of disease in months, median (IQR) 24 (12-48)
sd, standard deviation; IQR, interquartile range
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Table 2. The top 10 most mentioned functional activities of the PSFS compared 
to fixed-items questionnaires. The first row indicates that 14.4% of the items men-
tioned by the patients in the PSFS could be classified as recreation and leisure ac-
tivities on the ICF set for hand conditions. The last column represents whether these 
activities are evaluated by the DASH, PRWHE, MHQ or URAM. 
ICF items (N = 943)   % of total num-
ber of items
Items represented 
in de following 
questionnaires
D920 Recreation and leisure 
Eg. sports, music instrument, gardening
14.4 DASH, PRWHE
D410 Changing basic body position
Eg. pushing yourself up, lean on hand 7.3 PRWHE, URAM
D230 Carrying out daily routine
Eg. hand in pocket, opening a door
6.9 DASH, PRWHE, 
MHQ 
D540 Dressing
Eg. putting on gloves, button a shirt
6.4 PRWHE, MHQ
D430 Lifting and carrying objects
Eg. carrying a shopping bag
6.3 DASH, PRWHE, 
MHQ, URAM
D650 Using household objects
Eg. opening a jar
5.5 DASH, MHQ
D360 Using communication devices
Eg. typing, computer use
5.5 None
D7 Interpersonal interactions
Eg. shaking hands, clap hands
5.2 URAM
D520 Caring for body parts
Eg. wash your face or hair, to smear lotion 
4.4 DASH, PRWHE, 
MHQ, URAM
D4458 Hand and arm use 
Eg. using tools
4.2 DASH, PRWHE
ICF, International Classification of Function; PSFS, Patient Specific Functional Scale; DASH, Disabilities of the 
Arm, Shoulder and Hand Questionnaire; PRWHE, Patient Rated Wrist and Hand Evaluation; MHQ, Michigan 
Hand Questionnaire; URAM, Unité Rhumatologique des Affections de la Main
fidence interval 0.86-1.2), whereas the SRM of the total MHQ score was 0.58 
(0.42-0.74). The SRM of the MHQ subscales varied from 0.28 to 0.73 (Figure 
1). Ceiling effects were observed in the ‘ADL’- and ‘work’- subscales of the 
MHQ, whereas no floor or ceiling effects were observed in the PSFS (Table 4).
DISCUSSION
In this study we found that the PSFS has appropriate content validity for 
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Table 3. Sensitivity analyses. Comparison of the baseline characteristics of patients 








Mean age (years (sd)) 63 (8) 64 (10) 0.29
Sex (% male) 71 72 0.96
Surgery on dominant hand (%) 50 48 0.76
Positive family history (%) 47 46 0.99
Diabetes (%) 7 3 0.35
Smoking (%) 14 15 0.84
Occupational situation (%) 0.23
Unemployed/retired 53 51
Light (e.g. office work) 28 25
Medium (e.g. cleaning) 14 14
Heavy (e.g. construction work) 4 10
Type of surgery (%) 0.51
Limited fasciectomy 78 74
Needle fasciotomy 20 22
Limited fasciectomy & skingraft 2 5
Needle fasciotomy & lipofilling <1 0
Recurrent disease (%) 28 30 0.84
Duration of disease in months (medi-
an (IQR))
24 (12-48) 24 (12-48) 0.63
sd, standard deviation; IQR, interquartile range
patients with Dupuytren’s disease. In particular, patients mentioned problems 
in the ‘activities and participation’ domain of the ICF. Furthermore, the SRM of 
the PSFS was larger compared to the SRM of the total MHQ score, indicating 
better responsiveness to change of the PSFS.
In line with previous studies, we found a wide variety of functional problems 
in patients with Dupuytren’s disease, of which the majority is not covered by 
fixed-item patient reported outcomes measures like the MHQ.3,6,19,23 Most no-
tably, none of the fixed-item questionnaires assess the use of communication 
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Table 4. Outcome measurements collected as baseline and at 3 months post-op-
eratively. The p-value indicates the significance of the change from baseline to fol-
low-up. The last column indicates the number of patients with the highest score on 







 scores  
(mean (sd))





Number completed 308 208
Mean score 5.0 (2.2) 7.7 (2.1) <0.001 2.3
MHQ scores
Number completed 282 202
Hand function 64 (18) 71 (17) <0.001 6.4
ADL 85 (18) 89 (17) <0.001 22*
Work 83 (23) 83 (25) 0.90 44*
Pain 71 (22) 76 (21) <0.001 13
Aesthetics 70 (19) 82 (21) <0.001 9.2
Satisfaction 60 (25) 79 (22) <0.001 4.2
Total 72 (15) 80 (15) <0.001 0
Goniometry
Number completed 287 120
TAED (degrees) 67 (42) 20 (20) <0.001
sd, standard deviation; TAED, total active extension deficit. 
* indicate a ceiling effect
devices, despite the increasing use of such devices in modern day society. 
With several hundred separate functional problems mentioned by patients 
with Dupuytren’s disease, it is impossible to assess all patient specific prob-
lems with predefined questions. Therefore, the advantage of the PSFS is that 
it gains insight into the most important personal problems of the patient, 
making it a valuable additional instrument to plan therapy goals and to evalu-
ate the progress over time in a patient with Dupuytren’s disease. Remarkably, 
not all patients with Dupuytren’s disease experience functional problems, as 
indicated by the small group of patients (4,9%) who could not mention a func-
tional problem in the PSFS. These patients apparently seek medical treatment 
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for other reasons. Therefore, it is important to evaluate the complete aspect 
of the ICF, including body function (e.g., pain and range of motion), activities, 
participation, environmental- and personal factors. Although not explored 
in this study, previous studies have shown that problems such as pain and 
cosmetic concerns prompt patients to seek medical treatment and therefore 
should be considered when treating patients with Dupuytren’s disease.5
Fixed-item patient reported outcomes measures are widely used in health-
care to support better and more patient centred care, amongst other to as-
sess and compare the quality of providers and to provide data for evaluating 
practices.24 However, the present study clearly underlines the potential add-
ed value of individual patient reported outcomes measures like the PSFS, in 
particular to investigate patient specific change over time. However, due to 
the lack of item standardization, the PSFS may not be as useful for bench-
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PSFS, Patient Specific Funcional Scale; ADL, Activities of Daily Life
Figure 1. Standardized Response Mean of the PSFS and MHQ of patients who completed 
both questionnaires (n=197). Error bars represent the 95% confidence intervals. 
Standardized Response Mean
Figure 1. Standardized Response Mean of the PSFS and MHQ. Error bars represent 
the 95% confidence inte v l .
PSFS, Patient Specific Functional Scal; ADL, Activities of Daily Life
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The main strength of this study is the use of the PSFS alongside the MHQ, 
which enables direct comparison of the PSFS with a fixed-item patient report-
ed outcomes measures. Furthermore, this study has been conducted in a rel-
atively large population of patients with Dupuytren’s disease; measurements 
were performed as part of usual care in consecutive patients. Data therefore 
are likely to reflect all patients with Dupuytren’s disease, as compared to, for 
example, populations in many randomized controlled trials which have re-
stricted selection criteria. However, a drawback of the routine outcome mea-
surement setting is that patients may be less inclined to return for follow-up 
measurements and to fill out questionnaires. This could introduce missing 
values and therefore some potential bias. Despite this potential flaw, in fact 
our sensitivity analyses showed no differences in baseline characteristics 
between responders and non-responders in this study. A further limitation 
concerns the lack of a gold standard to evaluate the responsiveness of both 
questionnaires. The SRM is frequently used as responsiveness parameter.26 
However, the higher SRM of the PSFS may also be caused by factors unrelat-
ed to the ability of the instrument to detect changes in functional limitations 
(e.g. regression to the mean).25
In conclusion, this study demonstrates an appropriate content validity and 
good responsiveness of the PSFS. Self-generated items and the measure-
ment of such items allow reflecting the needs and problems of the individual 
patient and these characteristics make the PSFS a valuable additional tool to 
measure outcome in Dupuytren’s disease, which fits perfectly the ethos of 
patient-centred healthcare.
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Dupuytren’s disease: more than extension deficit
ABSTRACT
This study investigates the effect of the treatment of Dupuytren’s disease 
on the different domains of patient-reported hand function, such as hand 
appearance and satisfaction with hand function, and how these changes are 
associated with contracture reduction. Patients undergoing limited fasciecto-
my or percutaneous needle fasciotomy completed the Michigan Hand Out-
comes Questionnaire before and three months after surgery and straightness 
of the finger was assessed with a goniometer. Change scores for the various 
outcome parameters were calculated and linear regression analyses were 
used to examine associations between the change in extension deficit and 
change in MHQ-(sub)scores. The largest effects of surgery were seen in the 
change in extension deficit, the appearance of the hand and the satisfaction 
with the hand function. All associations remained weak with relatively low ex-
plained variances. This study underlines the importance of assessing other 




Hand surgical treatment options are focused on restoring the function of the 
upper extremity. Performance-based measures such as the improvement in 
range of motion or hand strength are widely used. They provide an objective 
measurement of the hand function at the function level of the International 
Classification of Function (ICF) model.1 Additionally, so-called patient-report-
ed outcome measures (PROMs) are used to assess hand function at activity 
and participation level of the ICF, reflecting the patient’ perspective of the 
impact of disease treatment on hand function.
In Dupuytren’s disease it is generally assumed that improvement of the 
hand function is an important goal for patients, with the aim to improve the 
range of motion of a finger or fingers (that is to reduce the contracture(s)). 
However, several studies have shown that an increase in range of motion is 
poorly correlated with an improvement in patient-reported hand function.2,3 
Comparative studies between various treatments have shown that, despite 
similar contracture reduction, differences exist in patient-assessed hand func-
tion and satisfaction with hand function.4,5 Thus improvement of patient-re-
ported hand function is not simply achieved by correcting the extension defi-
cit of patients.
While most Dupuytren studies focus on contracture correction and self-re-
ported hand function, several studies regarding rheumatoid arthritis have 
shown that post-operative hand appearance was an important determinant 
of post-operative satisfaction.6,7 Zhou et al.8 demonstrated that hand appear-
ance is an important predictor for patient satisfaction in Dupuytren’s disease. 
Kan et al.9 examined patients’ preferences for treatment and found that com-
plete contracture reduction was the most important attribute, but that pa-
tients were willing to trade up to almost 5% increase in recurrence rate and 
four degrees of residual contracture deficit for an excellent aesthetic result 
compared to a moderate result. This suggests, that other issues besides hand 
function are of importance to patients with Dupuytren’s disease.
Experienced clinicians may already recognize that aspects such as aes-
thetics play an important role, most PROMs in hand surgery solely assess 
hand function.10 For example, the Disability of the Arm, Shoulder and Hand 
questionnaire (DASH), does not assess hand appearance or satisfaction. The 
same is true for the only Dupuytren-specific PROM available, the Unité Rhu-
matologique des Affections de la Main (URAM).11 Other PROMs have a sin-
gle question, e.g. the Patient Evaluation Measure,12 on the appearance of the 
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hand, but these are included in a total score, making separate assessment of 
various issues impossible. However, the Michigan Hand Outcome Question-
naire (MHQ) has separate domains on hand appearance and satisfaction,13 
which make it possible to assess different domains of patient-reported hand 
function separately. 
We assess the effect of Dupuytren treatment on the different domains of 
patient-reported hand function as measured with the MHQ, and to assess to 
what extent change in the different domains of the MHQ is associated with 
the change in contracture correction.
METHODS
Study design
Patients who underwent either limited fasciectomy (LF) or percutaneous 
needle fasciotomy (PNF) for Dupuytren’s contractures between February 
2011 and June 2017 at a consortium of sixteen hand surgery practice sites 
in the Netherlands were selected from a prospectively maintained database 
designed for clinical and research purposes. Following the definition of Tang 
and Giddins, all surgeons can be considered specialists (dedicated hand 
surgeons with between two and twenty years of experience), including one 
expert in the field of Dupuytren’s disease.14 Total extension deficit of the af-
fected fingers was assessed prior to surgery and three months after surgery. 
Patients with baseline finger goniometry and a completed MHQ at baseline 
were eligible for this study. Patients with an affected thumb at baseline were 
not eligible, as problems with the thumb affect hand function very differently 
compared to other fingers. Patients with both, finger goniometry and a com-
pleted MHQ at follow-up were included in the final analyses. Patient- and 
disease-specific characteristics derived from this database were age, sex, 
occupational status, family history of Dupuytren’s disease, hand dominance, 
whether surgery was for primary or recurrent disease and type of surgery.
PROMs
As part of routine outcome measurement, patients were invited to com-
plete the Michigan Hand Outcome Questionnaire (MHQ) prior to surgery 
and three months afterwards.15 This thoroughly developed, hand-specific 
PROM assesses six domains of hand function: overall hand function, activities 
of daily living (ADL), work performance, pain, aesthetics and patient satisfac-
tion with hand function. All questions were answered by means of a five-point 
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Likert scale. Domain- and total scores, ranging from 0 (poorest function) to 
100 (best function), were calculated according to the questionnaire develop-
er’s instructions.15 Two reminders were mailed to non-responders. Only the 
scores pertaining to the treated side were used. As a measure of treatment ef-
fectiveness, the change between the pre- and post-operative PROM for each 
patient was calculated.
Total active extension deficit
The degree of total active extension deficit (TAED) was assessed by hand 
therapists during visits prior to surgery and 3 months after surgery by sum-
ming up the degree of active extension deficit at the metacarpophalangeal, 
proximal interphalangeal, and distal interphalangeal joint levels. Assessment 
prior to and after surgery could be done by either the same or a different 
hand therapist. Any hyperextension was converted to 0 degrees at an indi-
vidual joint level to prevent underestimation of the total degree of extension 
deficit. As a measure of treatment effectiveness, the change between the pre- 
and post-operative extension deficit for each patient was calculated. When 
multiple digits were affected, we used the measurements pertaining to the 
most severely contracted digit at baseline.
Statistical analyses
Cohen’s D effect sizes for paired data were calculated to facilitate compari-
son between the various outcome parameters. This standardized measure of 
effect describes the magnitude of change and can be interpreted as follows: 
0.20, small; 0.50, medium; 0.80, large effect size.16
The relationship between the change in finger goniometry and change in 
different (sub)scores of the MHQ was assessed using linear regression anal-
yses. For each MHQ-(sub)score, two separate models were used. In the first 
model, the change in the various MHQ-(sub)scores were introduced as the 
dependent variable and the change in extension deficit as the independent 
variable, along with the extension deficit at baseline prior to surgery to cor-
rect for baseline differences. In the second model, the above-mentioned pa-
tient- and disease parameters were added as independent variables to the 
first model to correct for potential confounding of the association studied 
in the first model. The explained variance was calculated of both models to 
assess to which extent the independent variables could explain the variance 
in MHQ-(sub)scores.
A power analyses for the multivariable linear regression models determined 
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Table 1. Patient characteristics (N = 1106)
Age in years, mean (sd) 63 (9)
Sex (% male) 75
Positive family history (%) 50
Occupational intensity (%)
Unemployed/retired 55
Light (e.g. office work) 28
Medium (e.g. cleaning) 13
Heavy (e.g. construction work) 5
Duration of disease in months, median (IQR) 24 (12-24) 
Recurrence (%) 21
Surgery on dominant hand (%) 53
Type of surgery (%)
Limited fasciectomy 79
Needle fasciotomy 21
Number of affected fingers (%)
1 54
2 35
3 or more 11





sd, standard deviation; IQR, interquartile range
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that a sample size of 394 patient would provide a power of 80% with 20 in-
dependent variables (to account for dummy variables) in the model, given 
a significance threshold of 0.05 and an expected explained variance of 5%.
RESULTS
At baseline, 2758 patients were eligible for this study. A total of 1106 pa-
tients completed both finger goniometry and the MHQ at follow-up and were 
included in this study. Patients had a mean age of 63 years (SD 9 years), 55% 
were retired or unemployed and 79% underwent limited fasciectomy (Table 
1). Post-operative finger goniometry of the most affected finger at baseline 
was not available in 110 patients (10%). These patients did return for follow 
up, but the treated finger was not entered in the database, possibly due to 
wrong labelling of the measurements.
The change in the different outcome measurements from baseline to fol-
low-up can be seen in Table 2. The mean TAED improved from 60 degrees 
prior to surgery to 20 degrees after surgery, which corresponds with a large 
effect size of 1.3. In the MHQ, the ‘aesthetics’- and ‘satisfaction’-subscales 
showed the largest improvements, with medium effect sizes of 0.54 and 0.61, 
respectively, while the changes in the more function-related subscales ‘gen-
eral hand function’ and ‘ADL’ were small with effect sizes of 0.29 and 0.12, 
respectively. The ‘work’-subscale showed no significant treatment effect at all.
Table 2. Outcome measurements at baseline and 3 months after surgery (N = 1106)
Baseline 3 months Effect 
Size
p-value
TAED in degrees, mean (sd)* 62 (36) 20 (22) 1.3 <0.0001
MHQ-subscales, mean (sd)
General hand function 68 (16) 72 (16) 0.29 <0.0001
ADL 90 (14) 91 (12) 0.12 <0.0001
Work 85 (21) 86 (21) 0.00 0.94
Pain 76 (20) 80 (19) 0.17 <0.0001
Aesthetics 71 (20) 83 (19) 0.54 <0.0001
Satisfaction 66 (24) 81 (21) 0.61 <0.0001
Total 76 (14) 82 (14) 0.46 <0.0001
TAED, Total Active Extension Deficit; sd, standard deviation; MHQ, Michigan Hand Outcome Questionnaire
* N = 996
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Linear regression (n = 996) showed a significant positive association be-
tween the change in extension deficit and the change subscales of the MHQ, 
as well as the total score of the MHQ, when corrected for the extension deficit 
at baseline (Table 3). However, the magnitude of this association was different 
for the different subscales. A reduction of the extension deficit with 40 de-
grees was associated with an increase of only 4 points in hand function-sub-
scale but 10 points in the aesthetics-subscale. Expressed as explained vari-
ance, we found that change in extension deficit explained less than 5% of the 
variance in each MHQ-(sub)scale, with the exception of the aesthetics-sub-
scale (6.5%) (Table 3: bottom row).
Adjusting for potential confounders had limited effect on any of the beta-co-
efficients in the association between change in extension deficit and change 
in MHQ-(sub)scores, suggesting no confounding of these variables on the 
associations (Table 4). In other words, there is no effect of other variables on 
the relation between the between change in extension deficit and change in 
MHQ-(sub)scores. The explained variance was between 6.1% and 9.2% for all 
subscales (Table 4: bottom row).
DISCUSSION
We found that the effect size of surgery on goniometry was more than 
double that of the patient-reported outcome measurements. Within the pa-
tient-reported outcome measurements, we found that a decrease in exten-
sion deficit mainly improved the appearance of the hand and the satisfaction 
with the hand function. General hand function and ADL subscales of the MHQ 
also improved, but less than subscales hand appearance and satisfaction with 
hand function and these effects may not be clinically relevant. All of the im-
provements in patient reported outcomes had a positive but weak associa-
tion with the improvement in extension deficit. Confounding by patient- and 
disease-specific characteristics was limited across most subscales. Most no-
tably, recurrent disease, the type of treatment and the number of affected 
fingers did not confound the associations between the improvements in the 
various subscales of the MHQ and the improvement in extension deficit. The 
association between the improvement in extension deficit and the improve-
ment in the ‘aesthetics’-subscale is the strongest association with the highest 
explained variance.
These results show that the appearance of the hand might be important 
to patients with Dupuytren’s disease, as is suggested by the large improve-
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ment in the ‘aesthetics’-subscale and the relative strong association with the 
improvement of finger goniometry compared to the more function-related 
subscales. This is in line with findings in patients with degenerative and in-
flammatory joint diseases or with traumatic injuries, which showed that de-
spite a clear loss in function, patients have concerns about hand appearance 
and disfigurements.17,18 For example, in rheumatoid arthritis, patients report-
ed larger improvements in appearance than function or pain relief after meta-
carpophalangeal joint arthroplasty.19 Since patients with Dupuytren’s disease 
develop contractures resulting in highly visible hand deformities, similarly 
to patients with hand osteoarthritis, this aesthetic discomfort in Dupuytren’s 
disease might be associated with depressive symptoms and poor health-re-
lated quality of life.20 The discrepancy between the improvement in the ‘gen-
eral hand function’-subscale and ‘satisfaction with hand function’-subscale is 
remarkable. This discrepancy suggests that patients separately assess their 
hand function and how satisfied they are with this function. A possible ex-
planation is that satisfaction is determined by multiple factors including the 
expectations and experience of a treatment, as well as psychological and 
emotional factors of a patient.21-23 
The very small effect in the ‘ADL’-subscale, indicating a lack of sensitivity 
for evaluating the treatment effect in Dupuytren’s disease, may be related to 
the specific, predefined tasks included in the relatively generic hand func-
tion measure. Patients with Dupuytren’s disease experience a broad range 
of functional problems, which are not covered by the items of the ADL sub-
scale of the MHQ. The specific tasks included in the MHQ might not be those 
tasks which are problematic in patients with Dupuytren’s disease and patients 
already score near the maximum score prior to treatment. The same prob-
lems occur in other questionnaires, like the DASH and URAM.24,25 A possible 
solution would be to use patient-specific PROMs, such as the Patient-Specif-
ic Functional Scale26 or the Canadian Occupational Performance Measure,27 
which allow patients to specify tasks with which they have difficulty and score 
their progress. Relating the improvement in these scores to the improvement 
in extension deficit may give a more accurate estimate to what extent the im-
provement in extension deficit really does improve the performance of tasks 
patients seek help for.
The large loss to follow-up (60%) is a limitation of this study. This may have 
led to under- or overestimation of the identified associations, as it is unknown 
if these patients represent a group with good or poor results. However, sen-
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sitivity analyses found no significant or clinically relevant differences in base-
line between patients included in this study (with both goniometry and MHQ 
at follow-up) and patients not included in this study (Supplementary Table 
S1). Similarly, no significant differences were seen in goniometry and minor 
differences (2 points or less) in MHQ scores between included patients and 
patients with partial follow-up measurements (with MHQ at follow-up, but no 
goniometry (n = 667) and vice versa (n = 225)) (Supplementary Table S2). A 
second limitation in this study is the possible lack of sensitivity in the various 
function related subscales. Lastly, three months might be too early to notice 
full functional recovery following fasciectomy. However, in patients with Du-
puytren’s disease the time to follow-up remains a trade-off between the time 
to full hand function recovery and the recurrence of Dupuytren’s disease, 
which could be as early as three months after surgery.28
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Age in years, mean (sd) 63 (9) 63 (10) 0.11
Sex (% male) 75 74 0.43
Positive family history (%) 50 51 0.66
Occupational intensity (%) 0.10
Unemployed/retired 55 51
Light (e.g. office work) 28 30
Medium (e.g. cleaning) 13 13
Heavy (e.g. construction work) 5 7
Duration of disease in months, median (IQR) 24 (12-24) 18 (10-36) 0.01
Recurrence (%) 21 22 0.82
Surgery on dominant hand (%) 53 53 0.78
Type of surgery (%) 0.07
Limited fasciectomy 79 76
Needle fasciotomy 21 24
Number of affected fingers (%) 0.01
1 54 60
2 35 31
3 or more 11 9
Most affected finger (%) 0.31
Index finger 1.5 2.1
Middle finger 11 9.8
Ring finger 28 31
Pink 60 56
TAED in degrees, mean (sd) 62 (36) 60 (39) 0.12
MHQ, mean (sd)
General hand function 68 (16) 68 (17) 0.80
ADL 90 (14) 89 (14) 0.13
Work 85 (21) 84 (23) 0.05
Pain 76 (20) 75 (22) 0.08
Aesthetics 71 (20) 70 (21) 0.41
Satisfaction 66 (24) 66 (24) 0.96
Total 76 (14) 75 (15) 0.19




Supplementary Table S2. Sensitivity analyses of the follow measurements of pa-
tients with partial follow-up (either goniometry or MHQ)
Included Excluded p-value
TAED in degrees, mean (sd) 20 (22)1 21 (19)2 0.49
MHQ-subscales, mean (sd) 3 4
General hand function 72 (16) 71 (18) 0.21
ADL 91 (12) 89 (15) 0.01
Work 86 (21) 84 (23) 0.08
Pain 80 (19) 77 (22) 0.03
Aesthetics 83 (19) 81 (20) 0.02
Satisfaction 81 (21) 79 (23) 0.07
Total 82 (14) 81 (16) 0.01
TAED, Total Active Extension Deficit; sd, standard deviation; MHQ, Michigan Hand Outcome Questionnaire 
1 N = 996
2 N = 252, excluded: no MHQ
3 N = 1106
4 N = 667, excluded: no goniometry
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ABSTRACT
Background
Return to work is potentially an important factor in assessing the success of 
treatment. However, little is known about the return to work after treatment for 
Dupuytren’s contracture. Therefore, the primary aim of this study is to assess 
return to work after limited fasciectomy and percutaneous needle fasciotomy. 
Methods
Patients who underwent either a limited fasciectomy or percutaneous nee-
dle fasciotomy were invited to complete a ‘return to work’-questionnaire at 
six weeks, three months, six months, and twelve months post-operatively. Me-
dian time to return to work was assessed using inverted Kaplan-Meier curves 
and hazard ratios were calculated with Cox regression models. Finally, a cost 
analysis was carried out in using the human capital method in order to deter-
mine indirect costs due to loss of productivity.
Results
We included 2.698 patients in the study, of which 53% were employed at 
intake and included in the follow-up. After one year of follow-up, 90% of the 
patients returned to work. Median time to return to work was two weeks after 
limited fasciectomy and within days after percutaneous needle fasciotomy. 
Furthermore, physically strenuous work, female sex, and higher age were as-
sociated with a longer time to return to work. Lost productivity per patient was 
estimated at €2614,43. 
Conclusion
The majority of patients returned to work after treatment for Dupuytren’s 
disease. Return to work is much faster after percutaneous needle fascioto-
my compared to limited fasciectomy. These findings can be used for more 





In Western countries, the prevalence of Dupuytren’s disease in the general 
population ranges between 1 and 32%,1 with an estimated prevalence in the 
Netherlands of approximately 22% in those above 50 years of age.2 Often 
affected patients seek medical advice due to impaired hand function caused 
by advanced contractures, which make it increasingly difficult to complete 
everyday activities.3 Treatment, either surgical or non-surgical, is focused on 
restoring hand function by reducing digital contractures. 
Even though Dupuytren’s disease commonly affects patients at an elderly 
age, more than half of the patients with Dupuytren’s disease are employed 
at the time of treatment.4 Furthermore, Bainbridge et al. reported that 57% of 
patients with Dupuytren’s disease report functional limitations affecting their 
work activities.5 Patient-reported outcome measures, such as the Disability of 
the Arm, Shoulder and Hand questionnaire (DASH) and the Michigan Hand 
Outcome Questionnaire (MHQ) can be used to assess disability and work 
performance from a patient’s perspective.6,7 
Besides work performance, return to work after treatment for Dupuytren’s 
contracture is an important factor in assessing the success of a treatment. 
Studies in different patient groups have demonstrated that return to work is 
positively associated with quality of life.8 Opsteegh et al. reported an overall 
return to work rate of 49% in a very small population. More insight into the 
return to work after treatment for Dupuytren’s disease would be beneficial 
when estimating the socio-economic burden of Dupuytren’s disease, as well 
as provide helpful information for shared decision-making. Therefore, the aim 
of this study is to evaluate time to return to work in patients with Dupuytren’s 
disease after undergoing a limited fasciectomy or percutaneous needle fasci-
otomy to study factors associated with differences in the return to work time 
and to calculate the indirect costs associated with absence from work. 
METHODS 
Study design
Patients treated for Dupuytren’s disease between November 2011 and Au-
gust 2017 were selected from a database maintained by Xpert Clinic, a con-
sortium of 16 hand clinics in the Netherlands. This database and its design 
have previously been described.9 In short, this database has the structure of 
an open inception cohort. The data is collected in a prospective matter and 
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analyzed retrospectively. Follow-up lasted until patients returned to work with 
a maximum follow-up of one year. Patients undergoing a limited fasciectomy 
or percutaneous needle fasciotomy (without fat grafting) were included in this 
study. All patients provided written informed consent for the use of their data. 
As part of the general intake procedure, patients were asked if they had 
paid employment. Furthermore, patients who had paid employment were 
asked to specify how strenuous their work was (light, medium or heavy; see 
Table 1 for examples given to patients). Finally, patients who had paid em-
ployment were invited to complete a ‘return to work’-questionnaire after 
treatment. Patient characteristics derived from this database were: age, sex, 
hand dominance, family history of Dupuytren’s disease, whether surgery was 
for primary or recurrent disease, which joints were affected, and the number 
of affected fingers. 
‘Return to work’ - questionnaire
As part of routine outcome measurements, patients with paid employ-
ment were invited to complete a ‘return to work’-questionnaire at 6 weeks, 3 
months, 6 months, and 12 months after treatment. Patients were asked if they 
returned to work and were given the following answer options: 1. Yes; 2. No, 
because of the hand/wrist problem I am currently being treated for; 3. No, 
because of something else. 
If answered with ‘Yes’, patients were asked the following questions: 
- How many hours per week do you usually work (per employment con-
tract)?
- How many hours per week are you currently working?
- How many weeks after starting your treatment did you return to your work?
- Are you currently doing your regular work or are (temporary) adjustments 
made to your work?
- How many weeks after starting your treatment did you return to your reg-
ular work?
If patients answered the initial question with ‘No, …’ (option 2 and 3), no 
further questions were asked. As this study focused on return to work after 
treatment for Dupuytren’s disease, we used answer options 1 and 2 for the 
analysis. This made for a more intuitive analysis. Moreover, “no, because of 
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something else” was the final answer in the follow-up in only a few cases, 
these patients were treated as lost to follow-up and therefore censored.
Cost analysis
In order to assess (indirect) costs associated with the absence of work after 
treatment for Dupuytren’s disease, a productivity cost analysis was carried out 
using the human capital method. In this method, every hour not worked due 
to illness and treatment is considered a lost hour of work. Loss of productivity 
is the product of lost work hours and average productivity costs per work 
hour.10 The total hours lost was calculated by multiplying the median time to 
return to work by the average working hours per week. In the Netherlands the 
cost of productivity per hour is € 32 for women and € 38 for men.11 The cost 
of productivity per hour was calculated using the weighted mean of produc-
tivity costs per hour. This translated to an average of € 37.01 per hour (83.5% 
males, 16.5% females) for the study population. 
Human capital method = total lost hours x loss of productivity costs per hour 
(Median time to return to work in weeks x average working hours per week) 
x loss of productivity costs per hour
Statistical analysis
Return to work was defined as working 100% of the contractual hours while 
performing regular work tasks. Time was defined as the self-reported number 
of weeks it took for patients to return to work. Inverted Kaplan-Meier curves 
were computed to determine the time to return to work overall and sub-
groups. Patients who withdrew or were lost from follow-up before return to 
work were censored when they completed their last follow-up.
In order to calculate hazard ratios, Cox regression models were created. 
Univariate and multivariable models were performed, including the follow-
ing factors: treatment, occupational intensity, age, sex, family history, domi-
nant hand, recurrent disease, the affected joints, and the number of affected 
fingers. A bivariate Cox model was computed for occupational intensity and 
type of surgery. The proportional hazard assumptions were checked for all 
Cox models with the Schoenfeld residual tests. If the proportional hazard as-
sumption was not satisfied, time-dependent variables were created by split-
ting these variables into three groups: 0 - 1 week, 1 - 8 weeks, and 8 - 52 
weeks. Cox regression models were stratified by these time-dependent vari-
ables. Effect plots were computed to illustrate the impact of different factors 
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Figure 1. Flowchart. 2968 patients underwent a limited fasciectomy or percuta-
neous needle fasciotomy of which 1565 (53%) patients had paid employment at 
intake. Of these, 1385patients completed the return to work (RTW) questionnaire. 





















without 100% RTW 
N = 11
Figure 1. Flowchart. 2968 patients underwent a limited fasciectomy or percutaneous needle 
fasciotomy of which 1565 (53%) patients had paid employment at intak . Of these, 1385 
patients completed the return to work (RTW) questio naire. 131 patient were censored due to 
withdrawal from follow-up before they returned to work.
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on the time to return to work. All models and curves were computed using R 
statistical programming (version 3.8.1).
RESULTS
We included 2968 patients in the study, of which 1565 (53%) patients were 
gainfully employed at intake. Of these, 1385 patients responded to the return 
to work questionnaire (Figure 1).
The mean age of the employed population was 57 years, most patients did 
light physical work (61%), and the majority of the population underwent a 
limited fasciectomy (79%) (Table 1). Overall, 50% of the patients returned to 
work by the two-week mark, 75% returned to work at four weeks, and 90% re-
turned to work at 10 weeks. 90% of the initial 1385 patients returned to work 
within 12 months. No additional patients returned to work after 30 weeks. 
During follow-up, 131 patients (119 limited fasciectomy, 12 percutaneous 
needle fasciotomy) were censored due to withdrawal or lost from follow-up 
before they returned to work. Eleven patients (nine limited fasciectomy, two 
percutaneous needle fasciotomy) did not return to work within one year of 
follow-up. The median return to work for patients who underwent a limited 
fasciectomy was two weeks (IQR 1-5 weeks), compared to a median return to 
work of zero weeks (IQR 0-1 weeks) for patients who underwent a percutane-
ous needle fasciotomy (Figure 2). The ‘zero weeks’ is due to a lack of precision 
in the answering options; patients were not able to answer the question with 
more precision than zero or one week. The ‘zero weeks’ therefore reflects a 
return to work within days after percutaneous needle fasciotomy. The overall 
median return to work based on occupational intensity was one week (IQR 
0-2 weeks), three weeks (IQR 1-6 weeks), and five weeks (IQR 2-16 weeks) 
for light, medium, and heavy physical work, respectively. Figures 3a and 3b 
illustrate the return to work based on occupational intensity for patients un-
dergoing a limited fasciectomy and needle fasciotomy, respectively.
The overall cost of loss of productivity per patient was € 2614.43, based on 
the time they were not able to attend work. For the patients who underwent 
limited fasciectomy, the cost of loss of productivity per patient was € 2638.64; 
for percutaneous needle fasciotomy, this number was €180.93. Based on oc-
cupational intensity, the cost of loss of productivity was € 1323.02 for light 
work, € 3697.85 for medium work, and € 6966.57 for heavy work.
The hazard ratios extracted from the Cox models, indicating the probability 
of one group returning to work, varied little between univariate and multi-
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Table 1. Patient characteristics (N = 1385)
Age in years, mean (sd) 57 (7)
Sex (male) 1156 (84%)
Type of surgery
Limited fasciectomy 1087 (79%)
Needle fasciotomy 298 (21%)
Occupational Intensity
Light (e.g. office work) 841 (61%) 
Medium (e.g. cleaning) 371 (27%)
Heavy (e.g. construction work) 173 (12%) 
Surgery on dominant hand 733 (53%)
Recurrent disease 328 (24%) 
Positive Family history 748 (54%)  
Number of affected fingers
1 738 (53%)
2 421 (30%)










variable models, indicating little confounding. Males returned to work sooner 
than females and younger patients returned to work sooner than their older 
counterparts (Table 2). Patients who had three or more fingers affected took 
longer to return to work. PIP involvement was not associated with a longer 
time to return to work. Time-dependent variables were calculated for ‘type of 
treatment’ and ‘occupational intensity’, as the proportional hazard assumption 
was not met for these two variables (Table 3). The hazard ratio between the 
type of treatment in time period 1 (0-1 week) was 3.18 (95% CI: 2.72- 3.74), in-
dicating that the probability of a patient who underwent a percutaneous nee-
dle fasciotomy to return to work in the first week after the surgery was 3.18 
times as high as a patient who underwent a limited fasciectomy. However, this 
effect was not observed in time period 3 (>8 weeks), meaning that after eight 
weeks, the type of treatment no longer influences the probability of returning 
to work. Similar results were observed for the occupational intensity, where in 
the first eight weeks (time period 1 and 2), patients who did more physically 
strenuous work had a lower probability of returning to work in comparison 
to patients who did less physically strenuous work. Effect plots illustrate the 
effect of ‘type of surgery’ and ‘occupational intensity’ on the return to work 
(Supplementary Figure 1 and 2).  
DISCUSSION
The aim of this study was to evaluate time to return to work after surgical 
treatment for Dupuytren’s contracture and the associated, indirect costs. We 
found that the median return to work after percutaneous needle fasciotomy 
and limited fasciectomy was within days and two weeks, respectively. In ad-
dition, physically strenuous work, female sex, older age, and three or more 
affected fingers are associated with a longer return to work times. The cost of 
loss of productivity per patient was €2614.43; the costs were lower in patients 
who underwent percutaneous needle fasciotomy compared to those who un-
derwent limited fasciectomy and increasing costs were observed in patients 
with more strenuous work.
Our findings on return to work in Dupuytren’s disease are in line with oth-
er, although limited, findings in literature. In a mixed population of hand 
patients, Opsteegh et al. reported an overall return to work of 49%, where 
the very small population of patients with Dupuytren’s contractures included 
in this study had a return to work of 100%.12 In our population, 90% of the 
patients returned to work. However, the patients not returning to work were 
mainly those who did not complete the follow-up and were censored accord-
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Figure 2. Inverted Kaplan-Meier curve for percutaneous needle fasciotomy (PNF) and 
limited fasciectomy (LF). The event is return to work. Complete follow-up is 52 weeks. No 
additional patients returned to work after 30 weeks. Number at risk implies the patients who could 
potentially return to work at a given time. Median return to work was within days and 2 weeks for 
PNF and LF, respectively. 25% returned to work 0 week and 1 weeks after PNF and LF, respectively. 
75% returned to work 1 week and 5 weeks after PNF and LF, respectively. 90% returned to work 4 





Figure 2. Inverted Kaplan-Meier curve for percutaneous needle fasciotomy (PNF) 
and limited fasciectomy (LF). Complete follow-up is 52 weeks. No additional pa-
tients returned to work after 30 weeks. Number at risk implies the patients who 
could potenti lly return to work at a given ti e. Median return to work was within 
days and 2 weeks for PNF and LF, respectively. 25% returned to work 0 week and 
1 weeks after PNF and LF, r sp c ively. 75% returned to work 1 w ek and 5 weeks 
after PNF and LF, respectively. 90% returned to work 4 weeks and 14 weeks after 
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Figure 3a. Inverted Kaplan-Meier curve for patients undergoing limited fasciectomy. The event is 
return to work. Complete follow-up is 52 weeks. No additional patients returned to work after 30 
weeks. Number at risk implies the patients who could potentially return to work at a given time. 
Median return to work for light, medium and heavy work was one week, four weeks and six weeks, 
respectively (dashed lines). Interquartile ranges for light, medium and heavy work were 1-3 weeks, 2-7 
weeks, 3-18 weeks, respectively.
Figure 3a. Inverted Kaplan-Meier curve for patients undergoing limited fasciecto-
my. Complete follow-up is 52 weeks. No additional patients returned to work after 
30 weeks. Number at risk implies the patients who could potentially return to work 
at a giv n time. Median return to work f r light, medi m and heavy work was one 
week, four weeks and six weeks, respectively (dashed lines). Interquartile ranges for 
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Figure 3b. Inverted Kaplan-Meier curve for patients undergoing needle fasciotomy. The event is 
returning to work. Complete follow-up is 52 weeks. No additional patients returned to work after 30 
weeks. Number at risk implies the patients who could potentially return to work at a given time. Median 
return to work for light, medium and heavy work was zero weeks, one week and two weeks, respectively 
(dashed lines). Interquartile ranges for light, medium and heavy work were 0-1 week, 0-2 weeks, 1-2 
weeks, respectively. Last patients able to return to work were censored at six months (or 26 weeks) 
before returning to work.
Figure 3b. Inverted Kaplan-Meier curve for patients undergoing needle fasciotomy. 
Complete follow-up is 52 weeks. No additional patients returned to work after 30 
weeks. Number at risk implies the patients who could potentially return to work at 
a given time M dian return to work for light, medium and heav work was zero 
weeks, one week and two weeks, respectively (dashed lines). Interquartile ranges 
for light, medium and heavy work were 0-1 week, 0-2 weeks, 1-2 eeks, respective-
ly. Last patie t  able to r turn t  work were censored at six months (or 26 weeks) 
before returning to work.
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Table 2. Hazard ratios of the non-time dependent variables with 95% confidence 
intervals (CI) in the univariate and multivariable models. The multivariable model 
included all mentioned variables, as well as the time dependent variables ‘type of 
treatment’ and ‘occupational intensity’ (see Table3).
Variables Univariate
 Hazard ratio (95% CI)
Multivariable
Hazard ratio (95% CI)
Age 1.0 (1.00- 1.01) 0.99 (0.98- 1.00)*
Female sex 0.80 (0.68- 0.94)* 0.74 (0.62- 0.88)*
Surgery on dominant hand 1.04 (0.93- 1.16) 0.96 (0.85- 1.08)
Recurrent disease 0.98 (0.87- 1.12) 1.04 (0.90- 1.20)
Family history 0.97 (0.87- 1.08) 0.98 (0.87- 1.10)
Number of affected fingers
1 REF REF
2 0.85 (0.75-0.97)* 0.88 (0.78-1.01)
3 or more 0.71 (0.57-0.88)* 0.72 (0.58-0.89)*
Affected joints
MCP REF REF
PIP 0.81 (0.68-0.96)* 1.11 (0.93-1.34)
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ingly. In contrast, those patients who did complete the follow-up almost all 
returned to work. The 90% of patients returning to work is, therefore, likely 
an underestimation of the total of patients returning to work. No patients re-
turning to work after 30 weeks highlights what has been previously found 
in work-related studies; the chance of returning to work decreases as time 
on sick leave increases.13,14 Percutaneous needle fasciotomy is less invasive 
and has a shorter recovery time than limited fasciectomy.15,16 Rodrigo et al. 
described a recovery time of 21-58 days for limited fasciectomy, defined as 
the time from operation to return to work, without further therapy.17 Patients 
who undergo percutaneous needle fasciotomy can use their hands optimally 
one week after surgery.18 Since 1976, when the study of Rodrigo et al. was 
published, the operation and postoperative practices have improved. Hovius 
et al. reported a return to work time of 2-4 weeks in patients with Dupuytren’s 
disease, similar to our findings.19 Other return to work research focuses on 
different patient populations: for example, Bruyns et al. found a mean time 
off work of 31 weeks in patients who had median or ulnar nerve damage. Pain 
is associated with a prolonged return to work but is not a typical symptom of 
Dupuytren’s disease,20 which may explain the relatively short return to work 
time in patients with Dupuytren’s disease compared to patients other hand 
problems.12,21,22 
In general, patients who have work which predominantly involves manual 
labor have longer periods off work compared to patients who predominantly 
work behind a desk21,23 after treatment for hand conditions or injuries, which 
is also reflected by the differences between the occupational intensity cate-
gories in the current study and can probably be explained by the different 
physical demands of the job.12,24 In our study, patients who had three or more 
affected fingers took longer to return to work. Although data on the extent of 
the surgery is not available, the involvement of more fingers arguably leads to 
a more extensive surgery, which leads to a longer recovery and postponed re-
turn to work. Interestingly, PIP involvement is not associated with a longer time 
to return to work. The effect on return to work is explained by other variables 
such as the type of treatment, as can been seen by the change in coefficients 
between the univariate and multivariable model. Patients with significant PIP 
involvement are probably more likely to undergo a limited fasciectomy which 
explains the longer return to work. Hovius et al. reported that males return to 
work sooner than females, supporting our findings.19 In the Netherlands men 
are more commonly the primary earner within the household,25 making their 
need to go back to work more pronounced. Increasing age is associated with 
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long-term sick leave.14,20 Getting older comes with many physical changes 
that can influence the return to work time; older patients often have more 
comorbidities, decreased physical function, and delayed recovery in compar-
ison to younger individuals.26 
Macaulay et al. reported risk-adjusted indirect costs of €2492,46 for patients 
with Dupuytren’s disease,27 a number comparable to our estimation. When 
compared to other common hand disorders, such as rheumatoid arthritis and 
carpometacarpal arthritis, the costs associated with loss of productivity are 
much less in Dupuytren’s disease.28,29 Costs of loss of productivity for those 
who underwent percutaneous needle fasciotomy were much lower than for 
those who underwent limited fasciectomy, which can be expected given the 
difference in median return to work time. However, recurrent contractures are 
more frequent after percutaneous needle fasciotomy,30 making the need for 
additional procedures and, thus, additional costs more likely. How this affects 
long-term costs is currently unknown and cannot be determined using his 
study, as follow-up is limited to one year. 
The current study indicates a shorter median time to return to work after 
a percutaneous needle fasciotomy compared to a limited fasciectomy. Al-
though this could be an important consideration for patients, return to work 
is not the only consideration in the decision for a certain treatment. Other 
important considerations could be complication rates, expected severity of 
complications, and recurrence rates. Furthermore, percutaneous needle fas-
ciotomy and limited fasciectomy have their own indications depending on 
the severity of the disease. Nonetheless, insight into the estimated time to 
return to work can be helpful in shared decision making for both patients and 
physicians. 
The main strengths of this study are the large sample size, the longitudinal 
nature of the data, and low loss to follow-up. However, this study does have 
some limitations. Absenteeism is most likely dependent on local legislation 
and guidelines. Sick leave is tightly regulated in The Netherlands. Most no-
tably, employers are obliged to pay a minimum of 70% of the employee’s 
monthly wage in the first two years of sickness or work disability. Moreover, 
many employers agreed to diverge from this rule and pay 100% of the wages 
during the first year of absence. However, strict rules are enforced to avoid 
abuse of these compensations, including obligatory visits to independent 
occupational physicians determining the employee’s ability to work and, if 
possible, reintegration to work by doing alternative tasks at work. In counties 
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where sick leave is regulated differently, other incentives to return to work 
might arise, such as pressure from employers to return to work or financial 
incentives, which might limit the generalizability of the current study. On the 
other hand, the effect of factors such as the type of surgery and type of work 
that we found in our study may still be similar across countries. Furthermore, 
information on whether patients were self-employed was not available. If a 
patient is self-employed, they do not benefit to the same extent from Dutch 
legislation and guidelines. These patients might have financial incentives to 
return to work earlier, unless they have insurance covering their sick leave, fur-
ther complicating matters. However, we assume that the potential influence 
of these rules and laws is limited as the current estimates for return to work 
showed a rapid return to work. Finally, the disease severity and the extent of 
the surgery could influence the return to work. To account for this, which joints 
are affected and the number of affected fingers are taken into account in the 
analysis. Although these factors do not completely correlate with disease se-
verity and extent of surgery, they most likely represent a significant portion of 
the extent of the surgery.  
In conclusion, this study demonstrates that return to work after treatment for 
Dupuytren’s contractures is high and relatively short for both needle fascioto-
my and limited fasciectomy, although much shorter after needle fasciotomy. 
In addition to the type of treatment, patients with physically demanding em-
ployment take longer to return to work. Furthermore, the cost of loss of pro-
ductivity for Dupuytren’s disease seems to be lower than for other illnesses. 
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Supplementary Figure 1. Probabilities of returning to work by a given point in time 
based on the multivariable model. To illustrate the effect of treatment, all other variables are kept 
constant. Here, the probability of returning to work by a given point in time of a 60-year old, 
male patient with primary disease of the dominant hand, light occupational intensity and 
positive family history is illustrated. The probability of this specific patient for returning to 
work after 52 weeks is 0.972 and 0.996 for LF and PNF, respectively.
Supplementary Figure 1. Probabilities of returning to work by a given point in time 
based on the multivariable model. To illustrate the effect of treatment, all other vari-
ables are kept constant. Here, the probability of returning to work by a given point 
in time of a 60-year old, male patient with primary disease of the dominant hand, 
light occupational intensity and positive family history is illustrated. The probability 





















Supplementary Figure 2. Probabilities of returning to work by a given point in time based 
on the multivariable model. To illustrate the effect of occupational intensity, all other variables 
are kept constant. Here, the probability of returning to work by a given point in time of a 60-year 
old, male patient with primary disease of the dominant hand and a positive family history 
undergoing a limited fasciectomy is illustrated. The probability of this specific patient for 
returning to work after 52 weeks is 0.972, 0.915 and 0.809 for light, medium and heavy work, 
respectively.
Supplementary Figure 2. Probabilities of returning to work by a given point in time 
based on the multivariable model. To illustrate the effect of occupational intensity, 
all other variables are kept constant. Here, the probability of returning to work by 
a given point in time of a 60-year old , male p tient with primary disease of the 
dominant hand and a positive family history undergoing a limited fasciectomy is il-
lustrated. The probability of this specific patient for returning to work after 52 weeks 
is 0.972, 0.915 and 0.809 for light, medium and heavy work, respectively.
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ABSTRACT
Background
There are multiple studies about the effectiveness of primary treatment in 
Dupuytren’s disease. However, such studies concerning treatment effective-
ness of recurrent disease are scarce. Therefore, the primary aim of this study is 
to compare treatment effectiveness of initial and repeated surgery in patients 
with Dupuytren’s disease.
Methods 
Patients who underwent both initial and repeated treatment were selected 
from a prospectively maintained database. Outcome measurements consist-
ed of finger goniometry, the Michigan Hand Outcomes Questionnaire (MHQ) 
and complications. Treatment effectiveness was defined as improvement in 
extension deficit and patient-reported hand function. In addition, measure-
ments at intake of both treatments were compared. Subgroup analysis were 
done to evaluate influence of type of surgery of initial treatment on outcomes 
of repeated treatment. 
Results
114 Patients were included in the final analyses. Improvement in extension 
deficit and MHQ outcomes was equal for initial and repeated treatments. Ex-
tension deficit and MHQ were worse at intake of repeated treatment com-
pared to these outcomes at intake of initial treatment. In addition, patients 
who initially underwent needle fasciotomy achieved a better contracture re-
duction after repeated treatment. 
Conclusion
This study demonstrates that treatment of recurrent Dupuytren’s disease 
is as effective as initial treatment, despite larger extension deficit and worse 
self-assessed hand function before undergoing repeated treatment. Com-
plication rates were similar for initial and repeated treatments. Furthermore, 
needle fasciotomy for initial treatment results in better outcomes of repeated 
treatment compared to patients who initially underwent limited fasciectomy. 
These findings can be used for a more evidence-based preoperative counsel-
ing with patients with recurrent Dupuytren’s disease. 
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INTRODUCTION
Dupuytren’s disease is a progressive disease of the hand involving fibrotic 
strands in the palmar fascia, which leads to formation of cords, nodules and 
contractures of the affected fingers and eventually loss of hand function.1,2 
Depending on various factors, such as the chosen operation and the aggres-
siveness of the disease, recurrence of contracture formation occurs over time, 
subsequently leading to deterioration of the hand function and the need for 
new treatment.3 
Although there is increasing evidence of primary treatment efficacy,4-6 little 
is known about the success of treatment of recurrent disease, i.e. to what ex-
tent the same reduction in contracture can be achieved. Two earlier studies 
on this topic showed that when percutaneous needle fasciotomy is used for 
repeated treatment it is just as effective as when it is used for initial treat-
ment.7,8 Other studies did subgroup analyses for different treatments in re-
current Dupuytren’s disease to evaluate whether they were equally effective, 
however these studies did not compare the effectiveness between initial and 
repeated treatment.4,9 Increasing this knowledge would benefit the preop-
erative counseling of patients with recurrent Dupuytren disease, as patients 
require well-balanced, preferably evidence-based, information to opt for a 
certain treatment. Furthermore, it is unknown how the contracture degree at 
intake compares to the degree of contracture on repeated treatment; knowl-
edge on this may indicate whether patients are inclined to elect surgery with 
a larger or smaller contracture at the second treatment. Also, it is unknown to 
what extent the success of repeated treatment is influenced by the treatment 
choice at initial treatment. For example, it has been argued that needle fas-
ciotomy has a relatively high recurrence rate but that recurrent surgery can 
be successfully performed after initial fasciotomy.7 However, a comparison of 
the success of recurrent surgery after different initial treatments has not been 
reported. 
The primary aim of this study is to compare differences in treatment effec-
tiveness of initial and repeated surgery in patients with Dupuytren’s disease. 
In addition, we will compare contracture rate and hand function at intake of 
initial and repeated treatment in the same patients, to determine if patients 
undergo surgery at different levels of contracture rates and hand function lev-
els. Furthermore, we will evaluate if the treatment effect of the repeated treat-
ment was different for patients that initially underwent limited fasciectomy or 
needle fasciotomy. 
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METHODS
Patient population
Patients were selected from a database with outcome data from a consor-
tium of 16 hand surgery practice sites in the Netherlands. This database with 
routine outcome measurement is designed for both clinical and research pur-
poses. Outcome measurements consisted of finger goniometry prior to treat-
ment and 3 months afterwards. Furthermore, patients were invited to com-
plete a PROM questionnaire prior to surgery and three months afterwards. 
Two reminders were mailed to non-responders.
We selected all patients who underwent initial treatment for Dupuytren’s 
contractures and repeated treatment for the recurrence of Dupuytren’s con-
tractures on the same finger(s) between 2011 and 2017 and with goniometry 
measurements on baseline of both treatments. No further exclusion criteria 
were applied. 
Patient- and disease-specific characteristics were derived from this data-
base including age, sex, occupational status, current tobacco and alcohol 
use, family history of Dupuytren’s disease and hand dominance. Complica-
tions for each treatment were documented and grouped in categories. The 
local institutional review board approved the study and all patients provided 
written informed consent. 
Treatment
Treatments were performed by certified hand surgeons, all with multiple 
years of experience in hand surgery. The timing and type of treatment was 
based on shared decision-making; the participating practice sites did not 
have specific guidelines concerning the timing and type of treatment. How-
ever, the Dutch guidelines do suggest limited fasciectomy as standard treat-
ment, where needle fasciotomy can be used in cases with a palpable cord 
and if patients accept the higher probability of a recurrence.10 The various 
treatments, being collagenase, needle fasciotomy, limited fasciectomy with-
out or with skin graft, were performed according to standardized protocols. 
A more extensive description of these treatments has been reported earlier 
in three comparative studies.4,9,11 All treatments were covered by healthcare 
insurances, except collagenase, which was for a short period temporarily pro-
vided by the manufacturer, leading to a short period that collagenase was 
administered to eligible patients. 
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Measurements
Certified hand therapists assessed the degree of total residual contracture. 
The degree of extension of isolated finger joints in the affected finger(s) was 
measured with a goniometer. The total residual contracture was calculated 
per finger as the sum of the deficit of the metacarpophalangeal, proximal in-
terphalangeal and distal interphalangeal joint (Total Active Extension deficit, 
TAED). Any measured hyperextension was converted to 0 degrees to prevent 
underestimation of the total active extension deficit. When multiple digits 
were affected, we only used the measurements pertaining to the most se-
verely contracted digit at intake. As a measure of treatment effectiveness, the 
change between the pre- and post-operative TAED was calculated for each 
patient. 
Patients completed the Michigan Hand Outcomes Questionnaire (MHQ) to 
assess the hand function from a patient perspective. This hand-specific PROM 
contains six domains of hand function: overall hand function, activities of daily 
living, work performance, pain, aesthetics and patient satisfaction with hand 
function. The questions are answered by means of a five-point Likert scale 
which is converted to a scale from 0 (poorest function) to 100 (best function) 
according to the questionnaire’s developer’s instructions.12 Only the scores 
pertaining to the treated side were used. As a measure of treatment effective-
ness, the change between the pre- and post-operative MHQ-(sub)scores was 
calculated for each patient. 
Statistical analyses
For the primary analysis, to compare differences in treatment effectiveness 
of initial and repeated surgery, we compared the change in scores in goni-
ometry and MHQ scores of both interventions using a student’s T-test for 
normally distributed data and a Wilcoxon signed rank test for non-normally 
distributed data. Distribution of the data was evaluated with histograms and 
QQ norm plots.
As a secondary analysis, we compared contracture rate and hand function at 
intake of initial and repeated treatment, to determine if patients undergo sur-
gery at different contracture rates and hand function levels. As above, we used 
the student’s T-test and Wilcoxon signed rank test, depending on whether or 
not the data is normally distributed, to determine any significant difference. 
Finally, we evaluated if the treatment effect of the repeated treatment was dif-
144
Dupuytren’s disease: more than extension deficit
ferent for patients that initially underwent fasciectomy or needle fasciotomy 
using either an unpaired t-test or Wilcoxon rang sum test, again depending 
on whether or not the data is normally distributed. The significance threshold 
for all tests was set at 0.05.
A power analyses was performed to calculate the necessary sample size for 
the primary analysis (comparison of treatment effectiveness). A sample size of 
34 patients would provide a power of 80%, given a significance threshold of 
0.05 and an expected effect size of 0.5 for the change in goniometry.
RESULTS
A total of 114 patients, 77 men and 37 women with a mean age of 59,5 
± 12 years, were included in the final analysis (Table 1). The mean time be-
tween the two successive operations was 114 ± 57 weeks. In the majority of 
the patients, the initial treatment was a needle fasciotomy (45%) or limited 
fasciectomy (40%), whereas most patients (79%) underwent a limited fasciec-
tomy for their recurrent contracture (Figure 1). No Boutonniere deformities 
Table. 1 Patient characteristics at baseline of initial and repeated treatment (N = 114)
Initial treatment Repeated treatment
Age (mean (sd)) 60 years (12)  62 years (12)
Sex (male) 66% 66%
Positive family history 57% 57%
Occupational intensity
Unemployed/retired 33% 47%
Light (e.g. office work) 40% 36%
Medium (e.g. cleaning) 17% 11% 
Heavy (e.g. construction work) 10% 6%
Surgery on dominant hand 58% 58%
Little finger most affected*
Limited fasciectomy 30 out of 47 (64%) 59 out of 92 (64%)
Needle fasciotomy 27 out of 53 (51%) 7 out of 16 (44%)
Collagenase 8 out of 12 (67%) 1 out of 1 (100%)
Dermatofasciectomy 2 out of 2 (100%) 4 out of 5 (80%)
*numbers reflect the number of cases where the little finger was most affected finger out of the total number 
of cases done with this procedure.
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or other abnormalities potentially confounding the data were seen. Various 
patients did not return for follow-up goniometry and/or did not complete the 
MHQ. Follow-up measurements for the goniometry were available in 57 and 
48 patients in the initial and repeated treatment, respectively. The MHQ was 
completed in 94 and 86 patients at the intake of the initial and repeated treat-
ment, respectively, and in 66 and 57 patients at follow-up.
After the initial treatment eight complications (7% of all initial treatments) 
were documented and after repeated treatment 16 complications (14% of 
all repeated treatments) were documented. When separating complications 
















































Figure 1. Distribution of the combination of initial and repeated treatments in percentag-
es. The x-axis indicates the initial treatments, the y-axis the repeated treatments. The numbers 
below the x-as indicate the distribution at initial treatment; the numbers left of the y-axis the 
distribution of the repeated treatment. This shows, for example, that 41% of the patients 
underwent a limited fasciectomy for their initial therapy and  80% limited fasciectomy for the 
repeated treatment. The numbers within the graph indicate the distributions of all possible 
combinations. This, for example, shows that the majority of patients (39%) underwent limited 
fasciectomy as both initial and repeated treatment and that 36% of the patients had needle 
fasciotomy as an initial treatment and limited fasciectomy for the repeated treatment. 
Figure 1. Distribution of the combination of initial and repeated treatments in per-
centages. The x-axis indicates the initial treatments, the y-axis the repeated treat-
ments. The numbers below the x-as indicate he dist ibution at initial reatment; he 
numbers left of the y-axis the dis ribution of the rep ated treat . This shows, 
for example, that 41% of the patients underwent a limited fasciectomy for their ini-
tial therapy and 80% limited fasciectomy for the repeated treatment. The numbers 
within the graph indicate the distributions of all possible combinations. This, for ex-
ample, shows that the majority of patients (39%) underwent limited fasciectomy as 
both initial and repeated treatment and that 36% of the patients had needle fasci-
otomy as an initial treatment and limit  fasciectomy for the repeat d tr atment. 
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Table 2. Number of complications grouped by timing and type of treatment. Other 
treatments included one collagenase injection (sensibility) and two dermofasciec-
tomies. For the initial treatment this group is not shown as no complications were 
seen in this group.











Sensibility1 1 2 4 1 2 
Scars/Adhesions2 3 0 3 0 0
Infection/Inflammation3 1 1 3 0 0
Other 0 0 24 0 15
Total 5 (11%) 3 (5.6%) 12 (13%) 1 (6.6%)
LF, Limited fasciectomy; PNF, percutaneous needle fasciotomy
1 Includes numbness, burning and tingling sensation, pain 
2 Includes scar contractions, hypertrophic scar tissue adhesions of tendons
3 Includes infection (with antibiotic treatment and/or surgical treatment) and prolonged inflammation
4 one transient winging of scapula (due to plexus block), one Swanneck deformity after surgery.
5 one transient winging of scapula (due to plexus block)
Table 3. Pre- and postoperative extension deficits for the initial and repeated treat-
ment. Total extension deficit is the sum of the deficit of the metacarpophalangeal, 
proximal interphalangeal and distal interphalangeal joint. For significance levels see 
Table 4.
Initial treatment Repeated treatment
Extension deficit in 
degrees (mean(sd))
Intake 3 months 
post-op
Intake 3 months 
post-op
MCP 22.6 (22.2) 3.0 (5.0) 22.1 (21.0) 4.5 (8.1)
PIP 27.8 (26.5) 18.4 (16.7) 34.9 (24.6) 19.0 (16.5)
Total 53.8 (29.7) 22.8 (17.2) 60.3 (28.2) 24.8 (18.7)
MCP, metacarpophalangeal joint; PIP, proximal interphalangeal joint
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had similar complication rates (Table 2) although no formal statistics were 
used to compare these groups as the number of complications is low. For ex-
ample, one more complication in the initial limited fasciectomy group would 
result in a complication rate of 13%, similar to the repeated limited fasciotomy 
group.
Comparison of the treatment effectiveness of initial and repeated surgery 
showed that both treatments equally improved contracture rate (Figure 2A, 
Table 3 and 4). Similarly, patient-reported hand function improved equal in 
both treatments in three subscales of the MHQ (Figure 2B and Table 4). 
In the secondary analysis, we compared contracture rate and hand func-
tion at intake of initial and repeated treatment. Prior to repeated treatment 
patients had, on average, a worse TAED of 6.5 degrees and worse patient-re-
ported hand function compared to before their initial treatment (Figure 2, 
Table 3 and 4). 
Finally, we evaluated whether the treatment effect of the repeated treatment 
was different for patients that initially underwent fasciectomy (n = 42) or nee-
dle fasciotomy (n = 52). Of the 42 patients who initially underwent a limited fa-
sciectomy, 83% underwent a limited fasciectomy in their repeated treatment 
again. The 52 patients who underwent a needle fasciotomy 75% underwent a 
limited fasciectomy for their repeated treatment. Evaluation of the subgroups 
showed that the contracture reduction in the repeated treatment was signifi-
cantly better in those patients that initially underwent a needle fasciotomy 
compared to those that underwent a limited fasciectomy, respectively 40 and 
24 degrees (p-value = 0.049; see right part of Figure 2A). 
DISCUSSION
This study found that the treatment of recurrent Dupuytren’s disease is as ef-
fective as the initial treatment in reducing contracture correction and improv-
ing patient-reported hand function. In addition, we found that patients with 
recurrent Dupuytren’s disease have a larger extension deficit and a worse 
self-assessed hand function before undergoing repeated treatment com-
pared to the initial treatment. Furthermore, our results suggest that patients 
who initially underwent needle fasciotomy had a better contracture reduction 
in their repeated treatment compared to those who initially underwent a lim-
ited fasciectomy.
To our knowledge, only two studies did examine post-operative results in 
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Figure 2. Pre- and postoperative measurements for the initial and repeated treatment. Both 
graphs indicate mean values at baseline and 3 month follow-up with error bars representing the 
standard deviation. 2A: goniometry of all treatment combined and for limited fasciectomy (LF) and 
needle fasciotomy (NF) separate. 2B: MHQ-score (points) and treatment effect (line) for the various 
subscales. For significance levels see Table 4. 
Figure 2. Pre- and postoperative measurements for the initial and repeated treat-
ment. Both graphs indicate mean values at baseline and 3 month follow-up with 
error bars representing the standard deviation. 2A: goniometry of all treatment 
combi ed and for limited fasciect my (LF) and ne dle fasciotomy (NF) separate. 
2B: MHQ-score (points) and treatment effect (line) for the various subscales. For sig-
nificance levels s  Table 4. 
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patients with recurrent contractures. However, both only focus on needle 
fasciotomy as repeated treatment, with the conclusion that needle fasciot-
omy can be applied effectively for recurrent disease.7,8 Therefore, our study 
provides new insights in the treatment of recurrent Dupuytren’s disease. The 
equal treatment effectiveness of the repeated surgery compared to the initial 
treatment shown in our study is important in the preoperative counseling of 
patients with recurrent Dupuytren’s disease.
At first sight, the complication rate appears to be twice as high after repeat-
ed treatment compared to initial treatment (14% against 7%). However, twice 
as much limited fasciectomies were performed as a repeated treatment, a 
procedure associated with more complications. When comparing complica-
tion rates in both limited fasciectomy and needle fasciotomy, they were equal 
for the initial and repeated treatment. The increase in limited fasciectomies in 
the repeated treatment might be because of various factors, such as surgeon 
Table 4. P-values for the various differences: between intake and 3 months post-
operative (first and second column), between the intake of the initial and repeated 
treatment (third column; primary analysis) and between the treatment effectiveness 
of the initial and repeated treatment (fourth column). The difference in treatment 
effectiveness between patients who underwent either LF or NF as initial treatment 
was significant (p-value = 0.049). All other differences were not significant (p-value 






















0.59 0.079 0.26 <0.01
ADL 0.94 0.76 0.61 <0.01
Pain 0.49 0.76 0.56 <0.01
Work 0.75 0.84 0.20 0.06
Aesthetics <0.01 <0.01 0.05 <0.01
Satisfaction <0.01 <0.01 0.45 <0.01
Total <0.01 <0.01 0.11 <0.01
TAED, Total Active Extension Deficit; ADL, Activities of Daily Living
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or patient preference. Nonetheless, this increase in limited fasciectomies is a 
likely explanation for the increase in complications and not merely the repeat-
ed treatment itself.
When comparing baseline function of the same patients between their ini-
tial treatment and repeated treatment, we found that both goniometry and 
the self-reported hand function was worse at the intake of the repeated treat-
ment. We did not investigate why this is the case and whether or not, for ex-
ample, disappointment of patients with the initial treatment results or a rel-
atively quick recurrence of the disease play a role. The lack of improvement 
after surgery in the various subscales of the MHQ might be the result of the 
lack of sensitivity or relative unimportance of these subscales for patients with 
Dupuytren’s disease.13 However, there was a clear improvement in satisfac-
tion with hand function. 
Patients who initially underwent needle fasciotomy achieved a better con-
tracture reduction after their repeated treatment compared to those who 
initially underwent limited fasciectomy. Although the observational nature of 
this study precludes hard conclusions, it has been suggested that the treat-
ment of early recurrent contractures after needle fasciotomy is less complicat-
ed because of less scar tissue.14,15 However, this does not mean that needle 
fasciotomy should be the primary procedure by default as other factors also 
play a role, such as that more severely affected patients are better off with 
more invasive treatments.14,16 At present, the choice of treatment will remain a 
trade-off between patient preference, e.g. fast recovery and recurrence rates, 
and physician preference, e.g. degree of contracture and type of strand. 
Strengths of this study are its prospective cohort; the relative large sample 
size compared to other studies and the use of both physician and patient-re-
ported outcome measurements. Unfortunately, despite the relative large 
sample size, the current cohort is not large enough to account for differences 
in treatment effectiveness by severity of disease (e.g., specific digits, joints in-
volved, degree of contracture). This would result in the analyses of very small 
subgroups. The design of the study limits itself to patients who present them-
selves at our clinic with recurrence of their Dupuytren’s contracture. Although 
the time to recurrence is relatively quick in this sample, this is in line with what 
has been previously described by Dias et al.17 Nonetheless, our population 
most likely represents an ‘early recontracture’ group,17 making it impossible 
to draw any conclusions about recurrent contractures in Dupuytren’s disease 
as a whole. While a strength of this study is a more natural disease course 
151
Hand Function in Recurrent Dupuytren’s Disease
compared to patients in a trial setting, a drawback is that patients could be 
less inclined to return for follow-up measurements and fill out questionnaires. 
This did introduce missing values and therefore some potential bias. Finally, 
data on scarring and capsulotomies is not available for our cohort. Further-
more, even if data on scarring was available, would very hard to objectively 
quantify. This will remain a challenge for further studies, as it might be an 
important variable.
In conclusion, this study demonstrates that treatment effectiveness is equal 
in both initial as repeated treatment - at three months follow up after each 
treatment - since post-operative results after repeated treatment were simi-
lar after initial treatment for both finger goniometry and hand function. This 
equality in effectiveness was achieved despite that patients have a larger fin-
ger contracture and a worse self-assessed hand function before undergoing 
repeated treatment. The complication rates for both limited fasciectomy and 
needle fasciotomy are equal in the initial and repeated treatments. In addi-
tion, our results suggest that patients who initially underwent needle fascioto-
my had a better contracture reduction in their repeated treatment compared 
to those who initially underwent a limited fasciectomy. These findings can be 
used for a better and more evidence-based preoperative counseling with pa-
tients with recurrent Dupuytren’s disease. 
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The general aims of this thesis were: to describe the data collection of the 
cohort of patients used for this thesis; to study to what extent psychological 
factors and context play a role in Dupuytren’s disease; to study alternative 
outcome measures in Dupuytren’s disease; to study to which extent post-op-
erative extension deficit can be reliably predicted in Dupuytren’s disease. 
The Discussion is structured accordingly in four parts: 1. The Hand and Wrist 
cohort, 2. Psychology and context, 3. Treatment and outcome, 4. Prediction. 
Afterwards, the general limitations of this thesis are discussed, followed by 
the future perspectives.
In Part 1, we provide insight in the Hand and Wrist Cohort. This routine out-
come measurement cohort, which forms the base of the studies performed 
in this thesis, has a similar structure as an open inception cohort and includes 
patients with a wide variety of hand- and wrist conditions. The cohort is unique 
in the field of hand- and wrist surgery due to its combination of size and detail 
of information per patient. More specific for this thesis, the cohort currently 
includes more than 3000 patients with Dupuytren’s disease with various out-
come measurements, such as total active extension deficit, patient-reported 
outcome measurements, return to work and satisfaction with outcome. In-
ception cohorts can be helpful in answering a multitude of clinically-relevant 
questions, but are especially powerful for prognostic studies and prediction 
modeling, which form the majority of this thesis. Furthermore, successful im-
plementation of routine outcome measurements in a clinic can provide direct 
feedback to both patients and physicians and might improve daily care.
In Part 2, we study to what extent psychological factors and context play a 
role in Dupuytren’s disease. We found that patients with Dupuytren’s disease 
do not perceive their illness as very threatening compared to other chronic 
hand disorders and to systemic diseases such as type 2 diabetes and glau-
coma.1-3 These findings suggest that preoperative interventions focused on 
changing illness perceptions may not be necessary for the large majority 
of patients with Dupuytren’s disease. On the other hand, we found that pa-
tients with Dupuytren’s disease who reported more positive experiences with 
the way their care was delivered, also showed more positive treatment out-
comes. A good experience with the communication of healthcare providers 
and treatment information had the strongest association with more positive 
treatment outcome. Optimizing communication and information in health-
care delivery is in our opinion  a valuable opportunity to improve outcomes.
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In Part 3, we underline the difficulties of assessing outcome after treatment 
for Dupuytren’s disease, as best illustrated by the lack of correlation between 
clinician-measured hand function and patient-reported hand function.4, 5 A 
possible explanation for this lack of correlation is that fixed-item PROMs com-
monly-used in Dupuytren’s disease might not evaluate the individual prob-
lems concerning patients with Dupuytren’s disease.6 This phenomenon can 
clearly be observed by the lack of improvement in the ADL- and work sub-
scales of the MHQ. This is further underlined by the wide range of functional 
problems reported by patients with Dupuytren’s disease, which are impossi-
ble to capture fully by pre-defined PROMs, such as the MHQ and the DASH 
and even the disease-specific URAM. 
To overcome this problem of traditional, pre-defined PROMs we used the 
Patient Specific Functional Scale (PSFS) in Dupuytren’s disease, a so-called 
individualized PROM relying on patient-generated items instead of pre-de-
fined, fixed items. Although conceptually completely different from tradition-
al PROMs, the PSFS promises to be a viable alternative for measuring pa-
tient-reported hand function in patients with Dupuytren’s disease. Potential 
difficulties with comparing patients who report a large variety of problems 
need further addressing. Nonetheless, the self-generated items and mea-
surement of such items, may better reflect the needs and problems of the in-
dividual patient and how they improve after treatment. These characteristics 
could make individualized PROMs, such as the PSFS, be the next step forward 
in patient-centered healthcare.
In addition to functional problems, very little is known about non-functional 
problems perceived by patients with Dupuytren’s disease. This might further 
explain the discrepancy between performance-based and patient-reported 
hand function. One of these problems might be hand appearance. Although 
often overlooked, the appearance of the hand is an essential part of human 
interaction, communication and social integration and might be a serious 
concern in patients with Dupuytren’s disease.7-9 This would be in line with 
results seen in rheumatoid arthritis, where surgery is usually performed for 
functional or pain-related problems, but were hand appearance showed the 
strongest relation with improvement in satisfaction.10, 11 In this thesis we have 
demonstrated that, from a patient’s perspective, the treatment of Dupuytren’s 
disease mainly improves the aesthetics of the hand and the satisfaction with 
the hand function. However, whether hand appearance is the main reason 
patient seek treatment for their contractures or if aesthetic improvement is 
183
General Discussion
just a positive side effect remains unknown.
More than half of the patients with Dupuytren’s disease are employed at 
the time of treatment. For these patients, return to work might be a relevant 
outcome parameter. We demonstrated that return to work after treatment for 
Dupuytren’s contractures is high and relatively soon after treatment for both 
needle fasciotomy and limited fasciectomy, although much sooner after nee-
dle fasciotomy than after fasciectomy, respectively within days and 2 weeks. 
This resulted in a much lower loss of productivity costs after a needle fasciot-
omy. However, recurrent contractures are more frequent after percutaneous 
needle fasciotomy, making the need for an additional procedure and thus 
additional costs more likely. In the absence of long-term data, this will remain 
unknown for the foreseeable future.
Despite the relatively high prevalence of recurrent contractures in Dupuy-
tren’s disease, little is known about treatment outcomes of recurrent contrac-
tures. In this thesis we demonstrated that repeated treatment was as effective 
as the initial treatment with similar complication rates. As treatment choice 
will remain a trade-off, e.g., between short recovery with higher recurrence 
rates vs. longer recovery with low recurrence rates, this information could 
benefit decision making as repeated treatments of the same finger do not 
seem to harm hand function after surgery.
In Part 4, we explored to what extent pre-operative patient- and disease 
characteristics can reliably predict post-operative outcomes. We demonstrat-
ed that contractures with a large baseline TAED and contractures in the PIP 
joint and 5th digit are challenging to correct. With the use of these parameters 
it is possible to reliably predict which patients achieve a straight finger after 
treatment, which could be helpful in illustrating patients what to expect from 
their treatment. Interestingly, variables such as age, sex and family history, 
which are part of the so-called Dupuytren’s diathesis,12 were not associat-
ed with complete finger extension directly after surgery. However, it is well 
known that these factors are associated with more aggressive forms of Dupu-
ytren’s disease and higher recurrence rates.12, 13 Therefore, these factors are 
still important to take into consideration when discussing treatment options 
with patients.
LIMITATIONS
The studies in this thesis have some limitations which are worth considering. 
The current cohort is the result of routine outcome measures collected as 
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part of daily clinical practice at a consortium of hand clinics. While a strength 
of this system is that the data is a more natural reflection of patients with Du-
puytren’s disease in clinical practice compared to patients in a trial setting, a 
drawback is that patients could be less inclined to return for follow-up mea-
surements and complete questionnaires. This did introduce missing values 
and therefore potential bias. The influence of this potential bias is hard to 
determine, especially compared to results of (randomized) clinical trials. The 
in- and exclusion criteria of these trials as well as the willingness of patients to 
participate in these trials does introduce selection of patients prior to entering 
the study. In our cohort all patients with baseline measurements are included 
and those who did not return for follow-up were lost. This study design also 
introduces selection of patients. Which study design is preferable most likely 
depends on the aim of the study. Although we believe that the potential bias 
in our studies is limited, as none of our sensitivity analyses showed any sig-
nificant effect, there is some baseline selection in our cohort. For example, 
patients with severe systemic disease (American Society of Anesthesiologists 
(ASA) classification of 3 or higher) cannot be treated in these clinics due to 
national laws and guidelines. However, there is currently no evidence that 
patients with systemic disease would have different outcomes. Furthermore, 
patients in the current cohort who were treated with collagenase are from 
a time when collagenase was introduced in the Netherlands and our clin-
ics were appointed as training centers. Afterwards, insurance companies in 
the Netherlands decided not to reimburse treatment with collagenase. This 
made the use of collagenase very limited in the Netherlands and severely 
limits our possibilities to study this treatment. 
Limitations more specific to Part 2 include the timing when the Illness Per-
ception Questionnaire (IPQ) was collected. Illness perception can be influ-
enced in many ways, starting with information about the disease, its progno-
sis and treatment options. As the IPQ was collected after patients received 
their diagnosis and information about the disease, the consulting physician 
would be able to influence the illness perception of patients. Furthermore, in 
the absence of an interventional study, it is impossible to provide a definitive 
conclusion about the direction of this association between treatment context 
and health outcome. With other words, it is impossible to tell if patients with 
a better experience will have a better outcome or visa versa.
Finally, specific to Part 4, complete finger extension was chosen as the out-
come of interest. However, the chance of achieving a straight finger after sur-
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gery is not the only consideration in the decision for a certain treatment. Oth-
er important considerations could be complication– and recurrence rates. 
Currently, none of the available treatments is superior across all consider-
ations, making the decision for a certain treatment a trade-off between these 
considerations. To aid this decision making each considerations requires de-
velopment of a specific prediction model with, most likely, different prognos-
tic variables. 
FUTURE PERSPECTIVES
Dupuytren’s disease will stay an interesting topic for research for the fore-
seeable future and many challenges lay ahead. First of all, there is current-
ly no definitive cure for Dupuytren’s disease. Although not the focus of this 
thesis and therefore not discussed, at least part of the research efforts made 
in the field of Dupuytren’s should focus on finding this cure and preventing 
the digital contractions associated with the disease. Besides this more funda-
mental research, Dupuytren’s disease is also of great interest to other fields 
of research. In contrast to most other hand disorders, Dupuytren’s disease 
is one of few hand disorders which has a clear, objective outcome measure 
in the form of extension deficit. This objective outcome measurement com-
bined with patient-reported outcome measurements serves as an intriguing 
platform for future research, whether it be evaluating the outcome of (new) 
surgical techniques or exploring the influence of psychological aspects in Du-
puytren’s disease. In the following paragraphs we will discuss future perspec-
tives related to this thesis.
In Part 1 we introduce the Hand and Wrist Cohort, which is currently unique 
within the field of hand and wrist disorders since it contains a large number of 
patients with a relatively great detail of data, covering both outcomes, treat-
ment information and patient characteristics. Further optimization of the cur-
rent cohort is possible by minimizing patient burden. A lower patient burden 
can potentially improve follow-up and reduce missing data. Furthermore, it 
would be of great value if more healthcare providers in hand and wrist care 
would routinely measure outcomes. Data of a variety of healthcare provid-
ers would lead to a more heterogenous study population and wider variety 
of treatments. This would facilitate comparison and collaborations between 
healthcare providers and researchers.
In Part 2 we examined the psychological aspects and influence of context in 
patients with Dupuytren’s disease. As literature in this field is relatively limited 
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for Dupuytren’s disease, multiple future research focuses are possible. First, 
it is worthwhile to evaluate other psychological aspects in patients with Du-
puytren’s disease. Of these psychological aspects, expectations might be the 
most interesting. Expectations are known to be an important aspect of place-
bo-like effects.14 It has been demonstrated that expectations can be modulat-
ed in various ways, which in turn can have beneficial effects on treatment.15-18 
The role of expectations in Dupuytren’s disease or hand surgery in general 
is currently unclear, but could play an important role in perceived hand func-
tion. Second, for most psychological aspects, it is unknown how they relate to 
hand function prior and after treatment. For example, it is unknown if patients 
who perceive their illness as more threatening also report a worse hand func-
tion in general or worse outcome after treatment. Insight into these relations 
could guide new treatment- and research strategies. Third and last, interven-
tional studies are needed to provide insight into the direction of the relation. 
Our study on the relation between healthcare delivery and treatment could 
not provide a definitive answer if there is a causal relation and its direction. A 
well-designed study where, for example, healthcare providers receive com-
munication training could provide insight into the direction of the relation.
In Part 3 we explored a variety of outcome parameters, including exten-
sion deficit, hand function from a patient’s perspective, hand appearance, 
return to work and outcome after repeated treatment. Future studies could 
focus on which parameter best capture the patient’s needs. The individual-
ized aspect of PROMs, such as the PSFS, overcomes limitations of fixed-item 
PROMs, such as the MHQ and DASH, when evaluating patients with Dupuy-
tren’s disease. Their flexible nature makes them ideal for evaluating the wide 
array of functional problems in Dupuytren’s disease. Furthermore, the PSFS 
is quick and easy to complete, making it interesting for further evaluation in 
the field of Dupuytren’s disease. Besides functional problems, an effort could 
be made in understanding non-functional problems in Dupuytren’s disease. 
Hand appearance might be a reason for patients to seek treatment, as the 
social burden associated with hand deformities is large. The evaluation of re-
current contractures and their treatment will remain challenging, as well-de-
signed, big cohorts with long term follow-up are needed to answer a number 
of questions. 
In Part 4 we demonstrated that a limited set of baseline characteristics can 
be used to reliably predict if a straight finger can be achieved after treatment. 
However, the decision for a certain treatment currently is a trade-off between 
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considerations such as complication rate, recurrence rates, and return-to-
work. Each of these outcome parameters requires its own model with, most 
likely, different variables. These models, or a combination of different mod-
els, could then be used in informing patients. Further research should focus 
on how to best use these models when informing patients, what effects this 
would have on the patients’ expectations and if the use of these models result 
in improvement of outcome. 
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Summary
This thesis explored various outcome measures in Dupuytren’s disease and 
their relationship with patient and disease characteristics and treatment out-
comes in order to better understand what matters to patients with Dupuy-
tren’s disease and what is important in the treatment of their disease. 
To do so, this thesis is structured in four parts: 1. introduction of the Hand 
and Wrist Cohort, 2. psychology and context, 3. treatment and outcome, 4. 
predicting outcome.
PART 1. INTRODUCTION OF THE HAND AND WRIST COHORT
The Hand and Wrist Cohort (Chapter 2) is a routine outcome measurement 
cohort, which has a similar structure as an open inception cohort. The cohort 
forms the base of the studies performed in this thesis. The data is collect-
ed at fixed times in the treatment of patients via web-based, open-source 
software. Besides a wide array of patient and disease characteristics, various 
outcome measurements are collected, including total active extension defi-
cit, patient-reported outcome measurements, return to work, and satisfaction 
with the outcome. The cohort currently holds over 52.000 patients. More spe-
cific for this thesis, it includes over 3000 patients with Dupuytren’s disease. In-
ception cohorts can be helpful in answering a multitude of clinically-relevant 
questions, but are especially powerful for prognostic studies and prediction 
modeling. Furthermore, successful implementation of routine outcome mea-
surements in a clinic can provide direct feedback to both patients and physi-
cians and might improve daily care.
PART 2. PSYCHOLOGY AND CONTEXT
Many psychologically-orientated factors potentially have a role in perceived 
hand function and in how patients respond to treatment. However, little is 
known about the influence of these factors in Dupuytren’s disease. This the-
sis focuses on two of those factors: illness perception and experience with 
healthcare delivery.
In Chapter 3, illness perceptions were explored in patients scheduled to 
undergo surgery for four major illnesses in hand surgery. The Brief Illness Per-
ception Questionnaire (Brief-IPQ) was used to rapidly assess the cognitive 
and emotional representation of the disorder in patients. On a scale ranging 
from zero (not threatening) to 80 (most threatening), the average Brief-IPQ 
sum scores for these subgroups were 42 for carpometacarpal osteoarthritis, 
28 for Dupuytren’s disease, 39 for carpal tunnel syndrome and 33 for trig-
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ger finger syndrome. These findings suggest that patients with Dupuytren’s 
disease do not perceive their illness as very threatening compared to oth-
er chronic hand disorders and that preoperative interventions focused on 
changing illness perceptions may not be necessary for the majority of pa-
tients with Dupuytren’s disease.
In Chapter 4, the experience with healthcare delivery was assessed using 
a patient-reported experience measure related to post-operative treatment 
outcomes assessed using the Michigan Hand Outcomes Questionnaire 
(MHQ) and the total active extension deficit. We found that a better expe-
rience with health care delivery was associated with better patient-reported 
outcomes while the association with residual extension deficit was minimal. 
A good experience with the communication of healthcare providers and 
treatment information had the strongest association with positive treatment 
outcomes. Experience with the treatment explained up to twelve percent of 
the variance in treatment outcome. These findings indicate that optimizing 
communication and information in healthcare delivery could be a valuable 
opportunity to improve outcomes.
PART 3. TREATMENT AND OUTCOME
Measuring and understanding what is important for a patient is fundamen-
tal to understand the burden of disease and the success of treatment. How-
ever, measuring outcome can be done in multiple ways, all with their unique 
advantages and pitfalls. This part of the thesis focuses on exploring some of 
these outcome measures.
Traditional, fixed-item PROMs may not capture all functional problems of pa-
tients with Dupuytren’s disease. The Patient-Specific Functional Scale (PSFS) is 
an individualized questionnaire that enables patients to specify those activi-
ties with which they have difficulty in daily life. In Chapter 5, the content valid-
ity and responsiveness of the PSFS were determined in patients with Dupuy-
tren’s disease. Content validity, assessed with the International Classification 
of Function scale, was appropriate for patients with Dupuytren’s disease. The 
responsiveness of the PSFS was superior to the responsiveness of the MHQ 
score, as indicated by a larger effect size (1.0 vs. 0.58). These results support 
the concept that measuring self-generated items may better reflect the needs 
and problems of the individual patient and how they improve after treatment. 
These characteristics could make individualized PROMs, such as the PSFS, be 
the next step forward in patient-centered healthcare. 
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In Chapter 6, the effect of the treatment of Dupuytren’s disease on the dif-
ferent domains of patient-reported hand function, such as hand appearance 
and satisfaction with hand function, is explored. The largest effects of surgery 
were seen in the change in extension deficit, the appearance of the hand, 
and the satisfaction with hand function. All associations between MHQ-(sub)
scores and extension deficit remained weak with relatively low explained vari-
ances. This study underlines the importance of assessing other domains than 
hand function in Dupuytren’s disease.
In Chapter 7, return to work after treatment for Dupuytren’s disease is as-
sessed. At intake, 53% of the patients with Dupuytren’s disease were gainfully 
employed. Within a year, 90% of those patients returned to work. Of those 
who underwent a limited fasciectomy, 50% returned to work after two weeks, 
while for the percutaneous needle fasciotomy, 50% returned to work after 
only one day. Physically strenuous work, female sex, and higher age were as-
sociated with a longer time to return to work. These results show that the ma-
jority of patients returned to work. The time to return to work is much shorter 
after a percutaneous needle fasciotomy compared to a fasciectomy. 
In Chapter 8, the treatment effectiveness of initial and repeated surgery in 
patients with Dupuytren’s disease is compared. Improvement in extension 
deficit and MHQ outcomes was equal for initial and repeated treatments. In 
addition, patients who initially underwent needle fasciotomy achieved a bet-
ter contracture reduction after repeated treatment. Complication rates were 
similar for initial and repeated treatments. The results suggest that repeated 
treatment in Dupuytren’s disease can be done with comparable effectiveness.
PART 4. PREDICTING OUTCOME
In Chapter 9, we explore to which extent pre-operative patient and disease 
characteristics can reliably predict if a straight finger will be obtained with sur-
gery for Dupuytren’s disease. For both limited fasciectomy and percutaneous 
needle fasciotomy, baseline extension deficit, the type of finger and affected 
joint, as well as the number of affected fingers, independently determine if a 
straight finger can be achieved. Classical patient characteristics, such as age 
and sex, had no additional predictive value. The models presented in this 
study provide reliable predictions and could be helpful in informing patients 
and managing their expectations.
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CONCLUSION
In conclusion, this thesis demonstrated that Dupuytren’s disease is more 
than simply an extension deficit of the finger. Many different outcome mea-
sures are available and many outside influences are involved. All of these mat-
ter to various extents. Which measurements and influences are important to 
which patients will remain the subject of further research. Finally, combining 
all this knowledge should enable us to predict which patients benefit most 
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Samenvatting
Dit proefschrift onderzocht verschillende uitkomstmaten bij de ziekte van 
Dupuytren en hun relatie met patiënt- en ziektekenmerken en behandelre-
sultaten om beter te begrijpen wat belangrijk is voor patiënten met de ziekte 
van Dupuytren en wat belangrijk is bij de behandeling van hun ziekte.
Om dit te doen is dit proefschrift gestructureerd in vier delen: 1. introductie 
van het ‘Hand and Wrist Cohort’, 2. psychologie en context, 3. behandeling en 
uitkomst, 4. voorspellen van uitkomsten.
DEEL 1. INTRODUCTIE VAN HET ‘HAND AND WRIST COHORT’
Het ‘Hand and Wrist Cohort’ (Hoofdstuk 2) is een cohort met routinema-
tige uitkomstmetingen, dat een vergelijkbare structuur heeft als een open 
inceptiecohort. Het cohort vormt de basis van de onderzoeken die in dit 
proefschrift zijn uitgevoerd. De gegevens worden op vaste tijden verzameld 
bij de behandeling van patiënten via web-based, open source software. 
Naast een breed scala aan patiënt- en ziektekenmerken, worden verschillen-
de uitkomstmetingen verzameld, waaronder de extensiebeperking van een 
vinger, door de patiënt gerapporteerde uitkomstmaten, terugkeer naar het 
werk en tevredenheid met de uitkomst. Het cohort heeft momenteel meer 
dan 52.000 patiënten. Meer specifiek voor dit proefschrift omvat het meer 
dan 3000 patiënten met de ziekte van Dupuytren. Inceptiecohorten kunnen 
nuttig zijn bij het beantwoorden van een groot aantal klinisch relevante vra-
gen, maar zijn vooral krachtig voor prognostische studies en voorspelling-
smodellering. Bovendien kan succesvolle implementatie van routinematige 
uitkomstmetingen in een kliniek directe feedback geven aan zowel patiënten 
als artsen en kan het zo de dagelijkse zorg verbeteren.
Deel 2. Psychologie en context
Veel psychologisch georiënteerde factoren spelen potentieel een rol in de 
waargenomen handfunctie en in hoe patiënten reageren op een behandel-
ing. Er is echter weinig bekend over de invloed van deze factoren op de ziek-
te van Dupuytren. Dit proefschrift richt zich op twee van die factoren: ziekte-
perceptie en zorgbeleving.
In Hoofdstuk 3 werd ziekteperceptie onderzocht bij patiënten die gep-
land waren voor een operatie voor vier belangrijke ziekten bij handchirurgie. 
De Brief Illness Perception Questionnaire (Brief-IPQ) werd gebruikt om snel 
de cognitieve en emotionele representatie van de stoornis bij patiënten te 
beoordelen. Op een schaal variërend van nul (niet bedreigend) tot 80 (meest 
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bedreigend), waren de Brief-IPQ somscores voor deze subgroepen gemid-
deld 42 voor carpometacarpale artrose, 28 voor de ziekte van Dupuytren, 39 
voor carpaal tunnelsyndroom en 33 voor trigger finger syndroom. Deze bev-
indingen suggereren dat patiënten met de ziekte van Dupuytren hun ziekte 
niet als zeer bedreigend ervaren in vergelijking met andere chronische han-
daandoeningen en dat preoperatieve interventies gericht op het veranderen 
van ziektepercepties mogelijk niet nodig zijn voor de meerderheid van de 
patiënten met de ziekte van Dupuytren.
In Hoofdstuk 4 werd de zorgbeleving beoordeeld aan de hand van pa-
tiënt-gerapporteerde scores gerelateerd aan postoperatieve behandelre-
sultaten, beoordeeld met behulp van de Michigan Hand Outcomes Ques-
tionnaire (MHQ) en het totale tekort aan actieve extensie. We ontdekten dat 
een betere zorgbeleving geassocieerd was met betere patiënt-gerapport-
eerde resultaten, terwijl de associatie met een tekort aan resterende extensie 
minimaal was. Een goede ervaring met de communicatie van zorgverleners 
en behandelinformatie had de sterkste associatie met positieve behandel-
resultaten. Ervaring met de behandeling verklaarde tot twaalf procent van 
de variantie in het behandelresultaat. Deze bevindingen geven aan dat het 
optimaliseren van communicatie en informatie in de gezondheidszorg een 
waardevolle kans kan zijn om de resultaten te verbeteren.
DEEL 3. BEHANDELING EN RESULTAAT
Het meten en begrijpen van wat belangrijk is voor een patiënt is van funda-
menteel belang om de ziektelast en het succes van de behandeling te begri-
jpen. Het meten van de resultaten kan echter op meerdere manieren worden 
gedaan, allemaal met hun unieke voordelen en valkuilen. Dit proefschrift richt 
zich op het verkennen van enkele van deze uitkomstmaten.
Traditionele patient-reported outcome measures (PROM’s) met vaste 
items bevatten mogelijk niet alle functionele problemen van patiënten met 
de ziekte van Dupuytren. De Patient-Specific Functional Scale (PSFS) is een 
geïndividualiseerde vragenlijst waarmee patiënten kunnen specificeren met 
welke activiteiten zij in het dagelijks leven moeite hebben. In Hoofdstuk 5 
worden de geschiktheid van de vragen (content validity) en responsiviteit van 
de PSFS bepaald bij patiënten met de ziekte van Dupuytren. De inhoud van 
de vragen, beoordeeld met de Internationale Classificatie van Functieschaal, 
was geschikt voor patiënten met de ziekte van Dupuytren. De responsiviteit 
van de PSFS was superieur aan de responsiviteit van de MHQ-score, zoals 
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aangegeven door een grotere effectsize (1,0 vs. 0,58). Deze resultaten onder-
steunen het concept dat het meten van zelf-gegenereerde items mogelijk 
beter aansluit bij de behoeften en problemen van de individuele patiënt en 
hoe deze verbeteren na behandeling. Deze kenmerken maken dat individu-
ele PROM’s, zoals de PSFS, van waarde kunnen zijn om een volgende stap 
voorwaarts te maken in patiëntgerichte gezondheidszorg.
In Hoofdstuk 6 wordt het effect van de behandeling van de ziekte van Du-
puytren op de verschillende domeinen van door de patiënt gerapporteerde 
handfunctie, zoals het uiterlijk van de hand en tevredenheid met de hand-
functie, onderzocht. De grootste effecten van chirurgie werden gezien in de 
verandering in extensiebeperkingen, het uiterlijk van de hand en de tevre-
denheid met de handfunctie. Alle associaties tussen MHQ- (sub)scores en ex-
tensie beperkingen bleven zwak met relatief lage verklaarde varianties. Deze 
studie onderstreept het belang van het beoordelen van andere domeinen 
dan de handfunctie bij de ziekte van Dupuytren.
In Hoofdstuk 7 wordt werkhervatting na behandeling van de ziekte van Du-
puytren beoordeeld. Bij opname had 53% van de patiënten met de ziekte van 
Dupuytren een baan. Binnen een jaar ging 90% van die patiënten weer aan 
het werk. Van degenen die een beperkte fasciectomie ondergingen, ging 
50% na twee weken weer aan het werk, terwijl voor de naaldfasciotomie 50% 
na slechts één dag weer aan het werk ging. Lichamelijk zwaar werk, vrouwelijk 
geslacht en hogere leeftijd waren geassocieerd met een langere tijd om weer 
aan het werk te gaan. Deze resultaten laten zien dat de meerderheid van de 
patiënten weer aan het werk ging. De tijd om weer aan het werk te gaan is 
veel korter na een naaldfasciotomie in vergelijking met een fasciectomie.
In Hoofdstuk 8 wordt de effectiviteit van de initiële en recidief behandel-
ing bij patiënten met de ziekte van Dupuytren vergeleken. Verbetering van 
extensie beperking en MHQ-resultaten was gelijk voor initiële en recidief 
behandelingen. Bovendien bereikten patiënten die aanvankelijk een naald-
fasciotomie ondergingen een betere contractuurvermindering na recidief 
behandeling. Complicaties waren vergelijkbaar voor initiële en recidief be-
handelingen. De resultaten suggereren dat recidief behandeling bij de ziekte 
van Dupuytren met vergelijkbare effectiviteit kan worden gedaan.
DEEL 4. RESULTAAT VOORSPELLEN
In Hoofdstuk 9 onderzoeken we in hoeverre preoperatieve patiënt- en 
ziektekenmerken betrouwbaar kunnen voorspellen of een rechte vinger kan 
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worden verkregen met een operatie voor de ziekte van Dupuytren. Voor 
zowel een beperkte fasciectomie als een naaldfasciotomie voorspellen vier 
kenmerken of een rechte vinger kan worden verkregen: de extensie beperk-
ing op baseline, welke vinger is aangedaan, welk gewricht is aangedaan en 
het aantal aangedane vingers. Klassieke patiëntkenmerken, zoals leeftijd en 
geslacht, hadden geen aanvullende voorspellende waarde. De modellen die 
in dit onderzoek worden gepresenteerd bieden betrouwbare voorspellingen 
en kunnen nuttig zijn bij het informeren van patiënten en het inspelen op hun 
verwachtingen.
CONCLUSIE
Concluderend toonde dit proefschrift aan dat de ziekte van Dupuytren meer 
is dan alleen een extensie beperking van de vinger. Er zijn vele verschillende 
uitkomstmaten beschikbaar en er zijn vele invloeden van buitenaf bij betrok-
ken. Al deze zaken zijn in verschillende mate van belang. Welke metingen en 
invloeden belangrijk zijn voor welke patiënten zal onderwerp van onderzoek 
blijven. Tenslotte zou het combineren van al deze kennis ons in staat moeten 
stellen te voorspellen welke patiënten het meest baat hebben bij welke be-
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